1
|
Slee MG, Rainey‐Smith SR, Villemagne VL, Doecke JD, Sohrabi HR, Taddei K, Ames D, Dore V, Maruff P, Laws SM, Masters CL, Rowe CC, Martins RN, Erickson KI, Brown BM. Physical activity and brain amyloid beta: A longitudinal analysis of cognitively unimpaired older adults. Alzheimers Dement 2024; 20:1350-1359. [PMID: 37984813 PMCID: PMC10917015 DOI: 10.1002/alz.13556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 10/13/2023] [Accepted: 10/23/2023] [Indexed: 11/22/2023]
Abstract
INTRODUCTION The current study evaluated the relationship between habitual physical activity (PA) levels and brain amyloid beta (Aβ) over 15 years in a cohort of cognitively unimpaired older adults. METHODS PA and Aβ measures were collected over multiple timepoints from 731 cognitively unimpaired older adults participating in the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Aging. Regression modeling examined cross-sectional and longitudinal relationships between PA and brain Aβ. Moderation analyses examined apolipoprotein E (APOE) ε4 carriage impact on the PA-Aβ relationship. RESULTS PA was not associated with brain Aβ at baseline (β = -0.001, p = 0.72) or over time (β = -0.26, p = 0.24). APOE ε4 status did not moderate the PA-Aβ relationship over time (β = 0.12, p = 0.73). Brain Aβ levels did not predict PA trajectory (β = -54.26, p = 0.59). DISCUSSION Our study did not identify a relationship between habitual PA and brain Aβ levels. HIGHLIGHTS Physical activity levels did not predict brain amyloid beta (Aβ) levels over time in cognitively unimpaired older adults (≥60 years of age). Apolipoprotein E (APOE) ε4 carrier status did not moderate the physical activity-brain Aβ relationship over time. Physical activity trajectories were not impacted by brain Aβ levels.
Collapse
Affiliation(s)
- Michael G. Slee
- Centre for Healthy AgeingHealthy Futures InstituteMurdoch UniversityMurdochWestern AustraliaAustralia
| | - Stephanie R. Rainey‐Smith
- Centre for Healthy AgeingHealthy Futures InstituteMurdoch UniversityMurdochWestern AustraliaAustralia
- School of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
- Australian Alzheimer's Research FoundationNedlandsWestern AustraliaAustralia
- School of Psychological ScienceUniversity of Western AustraliaCrawleyWestern AustraliaAustralia
| | - Victor L. Villemagne
- Department of Molecular Imaging & TherapyAustin HealthHeidelbergVictoriaAustralia
- Department of PsychiatryUniversity of PittsburghPittsburghPennsylvaniaUSA
- Centre for Precision HealthEdith Cowan UniversityJoondalupWestern AustraliaAustralia
| | - James D. Doecke
- The Australian e‐Health Research CentreCSIROHerstonQueenslandAustralia
| | - Hamid R. Sohrabi
- Centre for Healthy AgeingHealthy Futures InstituteMurdoch UniversityMurdochWestern AustraliaAustralia
- School of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
- Australian Alzheimer's Research FoundationNedlandsWestern AustraliaAustralia
- Department of Biomedical SciencesMacquarie UniversitySydneyNew South WalesAustralia
| | - Kevin Taddei
- School of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
- Australian Alzheimer's Research FoundationNedlandsWestern AustraliaAustralia
| | - David Ames
- The Florey Institute of Neuroscience and Mental HealthUniversity of MelbourneParkvilleVictoriaAustralia
- National Ageing Research InstituteParkvilleVictoriaAustralia
- Academic Unit for Psychiatry of Old AgeUniversity of MelbourneCarltonVictoriaAustralia
| | - Vincent Dore
- Department of Molecular Imaging & TherapyAustin HealthHeidelbergVictoriaAustralia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental HealthUniversity of MelbourneParkvilleVictoriaAustralia
- Cogstate LtdMelbourneVictoriaAustralia
| | - Simon M. Laws
- Centre for Precision HealthEdith Cowan UniversityJoondalupWestern AustraliaAustralia
- Collaborative Genomics and Translation GroupSchool of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
- Curtin Medical SchoolCurtin UniversityBentleyWestern AustraliaAustralia
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental HealthUniversity of MelbourneParkvilleVictoriaAustralia
| | - Christopher C. Rowe
- Department of Molecular Imaging & TherapyAustin HealthHeidelbergVictoriaAustralia
- The Florey Institute of Neuroscience and Mental HealthUniversity of MelbourneParkvilleVictoriaAustralia
| | - Ralph N. Martins
- School of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
- Australian Alzheimer's Research FoundationNedlandsWestern AustraliaAustralia
- Department of Biomedical SciencesMacquarie UniversitySydneyNew South WalesAustralia
| | - Kirk I. Erickson
- Department of PsychologyUniversity of PittsburghPittsburghPennsylvaniaUSA
| | - Belinda M. Brown
- Centre for Healthy AgeingHealthy Futures InstituteMurdoch UniversityMurdochWestern AustraliaAustralia
- School of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
- Australian Alzheimer's Research FoundationNedlandsWestern AustraliaAustralia
| |
Collapse
|
2
|
Odenkirk MT, Zheng X, Kyle JE, Stratton KG, Nicora CD, Bloodsworth KJ, Mclean CA, Masters CL, Monroe ME, Doecke JD, Smith RD, Burnum-Johnson KE, Roberts BR, Baker ES. Deciphering ApoE Genotype-Driven Proteomic and Lipidomic Alterations in Alzheimer's Disease Across Distinct Brain Regions. J Proteome Res 2024. [PMID: 38236019 DOI: 10.1021/acs.jproteome.3c00604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2024]
Abstract
Alzheimer's disease (AD) is a neurodegenerative disease with a complex etiology influenced by confounding factors such as genetic polymorphisms, age, sex, and race. Traditionally, AD research has not prioritized these influences, resulting in dramatically skewed cohorts such as three times the number of Apolipoprotein E (APOE) ε4-allele carriers in AD relative to healthy cohorts. Thus, the resulting molecular changes in AD have previously been complicated by the influence of apolipoprotein E disparities. To explore how apolipoprotein E polymorphism influences AD progression, 62 post-mortem patients consisting of 33 AD and 29 controls (Ctrl) were studied to balance the number of ε4-allele carriers and facilitate a molecular comparison of the apolipoprotein E genotype. Lipid and protein perturbations were assessed across AD diagnosed brains compared to Ctrl brains, ε4 allele carriers (APOE4+ for those carrying 1 or 2 ε4s and APOE4- for non-ε4 carriers), and differences in ε3ε3 and ε3ε4 Ctrl brains across two brain regions (frontal cortex (FCX) and cerebellum (CBM)). The region-specific influences of apolipoprotein E on AD mechanisms showcased mitochondrial dysfunction and cell proteostasis at the core of AD pathophysiology in the post-mortem brains, indicating these two processes may be influenced by genotypic differences and brain morphology.
Collapse
Affiliation(s)
- Melanie T Odenkirk
- Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27606, United States of America
| | - Xueyun Zheng
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington 99354, United States of America
| | - Jennifer E Kyle
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington 99354, United States of America
| | - Kelly G Stratton
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington 99354, United States of America
| | - Carrie D Nicora
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington 99354, United States of America
| | - Kent J Bloodsworth
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington 99354, United States of America
| | - Catriona A Mclean
- Anatomical Pathology, Alfred Hospital, Prahran, Victoria 3181, Australia
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria 3010, Australia
| | - Colin L Masters
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria 3010, Australia
| | - Matthew E Monroe
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington 99354, United States of America
| | - James D Doecke
- CSIRO Health and Biosecurity, Herston, Queensland 4029, Australia
| | - Richard D Smith
- Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington 99354, United States of America
| | - Kristin E Burnum-Johnson
- Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, Washington 99354, United States of America
| | - Blaine R Roberts
- Department of Biochemistry, Emory University, Atlanta, Georgia 30322, United States of America
- Department of Neurology, Emory University, Atlanta, Georgia 30322, United States of America
| | - Erin S Baker
- Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27514, United States of America
| |
Collapse
|
3
|
Wang Z, Lewis V, Stehmann C, Varghese S, Senesi M, McGlade A, Ellett LJ, Doecke JD, Eratne D, Velakoulis D, Masters CL, Collins SJ, Li Q. Alzheimer's disease biomarker utilization at first referral enhances differential diagnostic precision with simultaneous exclusion of Creutzfeldt-Jakob disease. Alzheimers Dement (Amst) 2024; 16:e12548. [PMID: 38352040 PMCID: PMC10862167 DOI: 10.1002/dad2.12548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Accepted: 12/19/2023] [Indexed: 02/16/2024]
Abstract
Most suspected Creutzfeldt-Jakob disease (CJD) cases are eventually diagnosed with other disorders. We assessed the utility of investigating Alzheimer's disease (AD) biomarkers and neurofilament light (NfL) in patients when CJD is suspected. The study cohort consisted of cerebrospinal fluid (CSF) samples referred for CJD biomarker screening wherein amyloid beta 1-42 (Aβ1-42), phosphorylated tau 181 (p-tau181), and total tau (t-tau) could be assessed via Elecsys immunoassays (n = 419) and NfL via enzyme-linked immunosorbent assay (ELISA; n = 161). In the non-CJD sub cohort (n = 371), 59% (219/371) had A+T- (abnormal Aβ1-42 only) and 21% (79/371) returned A+T+ (abnormal Aβ1-42 and p-tau181). In the 48 CJD subjects, a similar AD biomarker profile distribution was observed. To partially address the prevalence of likely pre-symptomatic AD, NfL was utilized to assess for neuronal damage. NfL was abnormal in 76% (25/33) of A+T- subjects 40 to 69 years of age, 80% (20/25) of whom had normal t-tau. This study reinforces AD as an important differential diagnosis of suspected CJD, highlighting that incorporating AD biomarkers and NfL at initial testing is worthwhile.
Collapse
Affiliation(s)
- Zitianyu Wang
- National Dementia Diagnostics Laboratory (NDDL), The Florey InstituteThe University of MelbourneParkvilleAustralia
- Australian National Creutzfeldt‐Jakob Disease Registry (ANCJDR), The Florey InstituteThe University of MelbourneParkvilleAustralia
| | - Victoria Lewis
- Australian National Creutzfeldt‐Jakob Disease Registry (ANCJDR), The Florey InstituteThe University of MelbourneParkvilleAustralia
- Department of Medicine, Clinical Sciences Building, Royal Melbourne Hospital (RMH)The University of MelbourneParkvilleAustralia
| | - Christiane Stehmann
- Australian National Creutzfeldt‐Jakob Disease Registry (ANCJDR), The Florey InstituteThe University of MelbourneParkvilleAustralia
| | - Shiji Varghese
- National Dementia Diagnostics Laboratory (NDDL), The Florey InstituteThe University of MelbourneParkvilleAustralia
| | - Matteo Senesi
- Australian National Creutzfeldt‐Jakob Disease Registry (ANCJDR), The Florey InstituteThe University of MelbourneParkvilleAustralia
- Department of Medicine, Clinical Sciences Building, Royal Melbourne Hospital (RMH)The University of MelbourneParkvilleAustralia
| | - Amelia McGlade
- Australian National Creutzfeldt‐Jakob Disease Registry (ANCJDR), The Florey InstituteThe University of MelbourneParkvilleAustralia
| | - Laura J. Ellett
- Australian National Creutzfeldt‐Jakob Disease Registry (ANCJDR), The Florey InstituteThe University of MelbourneParkvilleAustralia
| | | | - Dhamidhu Eratne
- National Dementia Diagnostics Laboratory (NDDL), The Florey InstituteThe University of MelbourneParkvilleAustralia
- Neuropsychiatry, John Cade BuildingRoyal Melbourne HospitalParkvilleAustralia
| | - Dennis Velakoulis
- Neuropsychiatry, John Cade BuildingRoyal Melbourne HospitalParkvilleAustralia
| | - Colin L. Masters
- National Dementia Diagnostics Laboratory (NDDL), The Florey InstituteThe University of MelbourneParkvilleAustralia
- Australian National Creutzfeldt‐Jakob Disease Registry (ANCJDR), The Florey InstituteThe University of MelbourneParkvilleAustralia
| | - Steven J. Collins
- National Dementia Diagnostics Laboratory (NDDL), The Florey InstituteThe University of MelbourneParkvilleAustralia
- Australian National Creutzfeldt‐Jakob Disease Registry (ANCJDR), The Florey InstituteThe University of MelbourneParkvilleAustralia
- Department of Medicine, Clinical Sciences Building, Royal Melbourne Hospital (RMH)The University of MelbourneParkvilleAustralia
| | - Qiao‐Xin Li
- National Dementia Diagnostics Laboratory (NDDL), The Florey InstituteThe University of MelbourneParkvilleAustralia
| |
Collapse
|
4
|
Huang X, Li Y, Fowler C, Doecke JD, Lim YY, Drysdale C, Zhang V, Park K, Trounson B, Pertile K, Rumble R, Pickering JW, Rissman RA, Sarsoza F, Abdel‐Latif S, Lin Y, Doré V, Villemagne V, Rowe CC, Fripp J, Martins R, Wiley JS, Maruff P, Mintzer JE, Masters CL, Gu BJ. Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease. Alzheimers Dement 2023; 19:2084-2094. [PMID: 36349985 PMCID: PMC10166765 DOI: 10.1002/alz.12813] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 08/24/2022] [Accepted: 09/02/2022] [Indexed: 11/10/2022]
Abstract
INTRODUCTION Blood-based diagnostics and prognostics in sporadic Alzheimer's disease (AD) are important for identifying at-risk individuals for therapeutic interventions. METHODS In three stages, a total of 34 leukocyte antigens were examined by flow cytometry immunophenotyping. Data were analyzed by logistic regression and receiver operating characteristic (ROC) analyses. RESULTS We identified leukocyte markers differentially expressed in the patients with AD. Pathway analysis revealed a complex network involving upregulation of complement inhibition and downregulation of cargo receptor activity and Aβ clearance. A proposed panel including four leukocyte markers - CD11c, CD59, CD91, and CD163 - predicts patients' PET Aβ status with an area under the curve (AUC) of 0.93 (0.88 to 0.97). CD163 was the top performer in preclinical models. These findings have been validated in two independent cohorts. CONCLUSION Our finding of changes on peripheral leukocyte surface antigens in AD implicates the deficit in innate immunity. Leukocyte-based biomarkers prove to be both sensitive and practical for AD screening and diagnosis.
Collapse
Affiliation(s)
- Xin Huang
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Yihan Li
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Christopher Fowler
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - James D. Doecke
- The Australian e‐Health Research CentreCSIROBrisbaneQueenslandAustralia
| | - Yen Ying Lim
- Turner Institute for Brain and Mental HealthSchool of Psychological SciencesMonash UniversityClaytonVictoriaAustralia
| | - Candace Drysdale
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Vicky Zhang
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Keunha Park
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Brett Trounson
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Kelly Pertile
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Rebecca Rumble
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - John W. Pickering
- Department of MedicineUniversity of OtagoNew Zealand and Department of Emergency MedicineChristchurch HospitalChristchurchNew Zealand
| | - Robert A. Rissman
- Department of NeurosciencesUniversity of CaliforniaSan DiegoCaliforniaUSA
| | - Floyd Sarsoza
- Department of NeurosciencesUniversity of CaliforniaSan DiegoCaliforniaUSA
| | - Sara Abdel‐Latif
- Alzheimer's Therapeutic Research InstituteUniversity of Southern CaliforniaSan DiegoCaliforniaUSA
| | - Yong Lin
- National Clinical Research Center for Aging and MedicineHuashan HospitalFudan UniversityShanghaiChina
| | - Vincent Doré
- The Australian e‐Health Research CentreCSIROBrisbaneQueenslandAustralia
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia, and Department of Medicinethe University of MelbourneMelbourneAustralia
| | - Victor Villemagne
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia, and Department of Medicinethe University of MelbourneMelbourneAustralia
| | - Christopher C. Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Australia, and Department of Medicinethe University of MelbourneMelbourneAustralia
| | - Jurgen Fripp
- The Australian e‐Health Research CentreCSIROBrisbaneQueenslandAustralia
| | - Ralph Martins
- Centre of Excellence for Alzheimer's Disease Research and CareSchool of Medical and Health SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia
| | - James S. Wiley
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Paul Maruff
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
- CogState Ltd.MelbourneVictoriaAustralia
| | | | - Colin L. Masters
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
| | - Ben J. Gu
- The Florey Institute of Neurosciencethe University of MelbourneParkvilleVictoriaAustralia
- National Clinical Research Center for Aging and MedicineHuashan HospitalFudan UniversityShanghaiChina
| |
Collapse
|
5
|
Muller Bark J, Karpe AV, Doecke JD, Leo P, Jeffree RL, Chua B, Day BW, Beale DJ, Punyadeera C. A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients. Cancer Med 2023. [PMID: 37031458 DOI: 10.1002/cam4.5857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Revised: 03/04/2023] [Accepted: 03/14/2023] [Indexed: 04/11/2023] Open
Abstract
BACKGROUND Despite aggressive treatment, more than 90% of glioblastoma (GBM) patients experience recurrences. GBM response to therapy is currently assessed by imaging techniques and tissue biopsy. However, difficulties with these methods may cause misinterpretation of treatment outcomes. Currently, no validated therapy response biomarkers are available for monitoring GBM progression. Metabolomics holds potential as a complementary tool to improve the interpretation of therapy responses to help in clinical interventions for GBM patients. METHODS Saliva and blood from GBM patients were collected pre and postoperatively. Patients were stratified conforming their progression-free survival (PFS) into favourable or unfavourable clinical outcomes (>9 months or PFS ≤ 9 months, respectively). Analysis of saliva (whole-mouth and oral rinse) and plasma samples was conducted utilising LC-QqQ-MS and LC-QTOF-MS to determine the metabolomic and lipidomic profiles. The data were investigated using univariate and multivariate statistical analyses and graphical LASSO-based graphic network analyses. RESULTS Altogether, 151 metabolites and 197 lipids were detected within all saliva and plasma samples. Among the patients with unfavourable outcomes, metabolites such as cyclic-AMP, 3-hydroxy-kynurenine, dihydroorotate, UDP and cis-aconitate were elevated, compared to patients with favourable outcomes during pre-and post-surgery. These metabolites showed to impact the pentose phosphate and Warburg effect pathways. The lipid profile of patients who experienced unfavourable outcomes revealed a higher heterogeneity in the abundance of lipids and fewer associations between markers in contrast to the favourable outcome group. CONCLUSION Our findings indicate that changes in salivary and plasma metabolites in GBM patients can potentially be employed as less invasive prognostic biomarkers/biomarker panel but validation with larger cohorts is required.
Collapse
Affiliation(s)
- Juliana Muller Bark
- Faculty of Health, Centre for Biomedical Technologies, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia
- Saliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery - Griffith University, Brisbane, Queensland, Australia
- Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Gardens Point, Queensland, Australia
| | - Avinash V Karpe
- Environment, Commonwealth Scientific and Industrial Research Organization (CSIRO), Ecosciences Precinct, Dutton Park, Queensland, Australia
- Agriculture and Food, Commonwealth Scientific and Industrial Research Organization (CSIRO), Acton, Australian Capital Territory, Australia
| | - James D Doecke
- Australian eHealth Research Centre, CSIRO. Level 7, Surgical Treatment and Rehabilitation Service - STARS, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
| | - Paul Leo
- Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Gardens Point, Queensland, Australia
- Faculty of Health, Translational Genomics Group, School of Biomedical Sciences, Queensland University of Technology, Woolloongabba, Australia
| | - Rosalind L Jeffree
- QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
- Faculty of Medicine, University of Queensland, Herston, Queensland, Australia
- Kenneth G. Jamieson Department of Neurosurgery, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
- Cell and Molecular Biology Department, Sid Faithfull Brain Cancer Laboratory, QIMR Berghofer MRI, Brisbane, Queensland, Australia
| | - Benjamin Chua
- Faculty of Medicine, University of Queensland, Herston, Queensland, Australia
- Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
| | - Bryan W Day
- Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Gardens Point, Queensland, Australia
- Faculty of Medicine, University of Queensland, Herston, Queensland, Australia
- Cell and Molecular Biology Department, Sid Faithfull Brain Cancer Laboratory, QIMR Berghofer MRI, Brisbane, Queensland, Australia
| | - David J Beale
- Environment, Commonwealth Scientific and Industrial Research Organization (CSIRO), Ecosciences Precinct, Dutton Park, Queensland, Australia
| | - Chamindie Punyadeera
- Saliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery - Griffith University, Brisbane, Queensland, Australia
- Menzies Health Institute, Griffith University, Southport, Queensland, Australia
- Translational Research Institute, Woolloongabba, Queensland, Australia
| |
Collapse
|
6
|
Chatterjee P, Pedrini S, Doecke JD, Thota R, Villemagne VL, Doré V, Singh AK, Wang P, Rainey-Smith S, Fowler C, Taddei K, Sohrabi HR, Molloy MP, Ames D, Maruff P, Rowe CC, Masters CL, Martins RN. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement 2023; 19:1117-1134. [PMID: 36574591 DOI: 10.1002/alz.12724] [Citation(s) in RCA: 38] [Impact Index Per Article: 38.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 05/22/2022] [Accepted: 05/23/2022] [Indexed: 12/29/2022]
Abstract
INTRODUCTION Plasma amyloid beta (Aβ)1-42/Aβ1-40 ratio, phosphorylated-tau181 (p-tau181), glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are putative blood biomarkers for Alzheimer's disease (AD). However, head-to-head cross-sectional and longitudinal comparisons of the aforementioned biomarkers across the AD continuum are lacking. METHODS Plasma Aβ1-42, Aβ1-40, p-tau181, GFAP, and NfL were measured utilizing the Single Molecule Array (Simoa) platform and compared cross-sectionally across the AD continuum, wherein Aβ-PET (positron emission tomography)-negative cognitively unimpaired (CU Aβ-, n = 81) and mild cognitive impairment (MCI Aβ-, n = 26) participants were compared with Aβ-PET-positive participants across the AD continuum (CU Aβ+, n = 39; MCI Aβ+, n = 33; AD Aβ+, n = 46) from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) cohort. Longitudinal plasma biomarker changes were also assessed in MCI (n = 27) and AD (n = 29) participants compared with CU (n = 120) participants. In addition, associations between baseline plasma biomarker levels and prospective cognitive decline and Aβ-PET load were assessed over a 7 to 10-year duration. RESULTS Lower plasma Aβ1-42/Aβ1-40 ratio and elevated p-tau181 and GFAP were observed in CU Aβ+, MCI Aβ+, and AD Aβ+, whereas elevated plasma NfL was observed in MCI Aβ+ and AD Aβ+, compared with CU Aβ- and MCI Aβ-. Among the aforementioned plasma biomarkers, for models with and without AD risk factors (age, sex, and apolipoprotein E (APOE) ε4 carrier status), p-tau181 performed equivalent to or better than other biomarkers in predicting a brain Aβ-/+ status across the AD continuum. However, for models with and without the AD risk factors, a biomarker panel of Aβ1-42/Aβ1-40, p-tau181, and GFAP performed equivalent to or better than any of the biomarkers alone in predicting brain Aβ-/+ status across the AD continuum. Longitudinally, plasma Aβ1-42/Aβ1-40, p-tau181, and GFAP were altered in MCI compared with CU, and plasma GFAP and NfL were altered in AD compared with CU. In addition, lower plasma Aβ1-42/Aβ1-40 and higher p-tau181, GFAP, and NfL were associated with prospective cognitive decline and lower plasma Aβ1-42/Aβ1-40, and higher p-tau181 and GFAP were associated with increased Aβ-PET load prospectively. DISCUSSION These findings suggest that plasma biomarkers are altered cross-sectionally and longitudinally, along the AD continuum, and are prospectively associated with cognitive decline and brain Aβ-PET load. In addition, although p-tau181 performed equivalent to or better than other biomarkers in predicting an Aβ-/+ status across the AD continuum, a panel of biomarkers may have superior Aβ-/+ status predictive capability across the AD continuum. HIGHLIGHTS Area under the curve (AUC) of p-tau181 ≥ AUC of Aβ42/40, GFAP, NfL in predicting PET Aβ-/+ status (Aβ-/+). AUC of Aβ42/40+p-tau181+GFAP panel ≥ AUC of Aβ42/40/p-tau181/GFAP/NfL for Aβ-/+. Longitudinally, Aβ42/40, p-tau181, and GFAP were altered in MCI versus CU. Longitudinally, GFAP and NfL were altered in AD versus CU. Aβ42/40, p-tau181, GFAP, and NfL are associated with prospective cognitive decline. Aβ42/40, p-tau181, and GFAP are associated with increased PET Aβ load prospectively.
Collapse
Affiliation(s)
- Pratishtha Chatterjee
- Macquarie Medical School, Macquarie University, North Ryde, New South Wales, Australia
- School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
| | - Steve Pedrini
- School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
| | - James D Doecke
- Australian eHealth Research Centre, CSIRO, Brisbane, Queensland, Australia
| | - Rohith Thota
- Macquarie Medical School, Macquarie University, North Ryde, New South Wales, Australia
- School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, New South Wales, Australia
| | - Victor L Villemagne
- Department of Psychiatry, University of Pittsburgh, Pennsylvania, Pittsburgh, USA
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia
| | - Vincent Doré
- Australian eHealth Research Centre, CSIRO, Brisbane, Queensland, Australia
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia
| | - Abhay K Singh
- Macquarie Business School, Macquarie University, North Ryde, New South Wales, Australia
| | - Penghao Wang
- College of Science, Health, Engineering and Education, Murdoch University, Perth, Western Australia, Australia
| | - Stephanie Rainey-Smith
- School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
- Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia
- Centre for Healthy Ageing, Murdoch University, Perth, Western Australia, Australia
- School of Psychological Science, University of Western Australia, Crawley, Western Australia, Australia
| | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Kevin Taddei
- School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
- Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia
| | - Hamid R Sohrabi
- Macquarie Medical School, Macquarie University, North Ryde, New South Wales, Australia
- School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
- Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia
- School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Western Australia, Australia
- Centre for Healthy Ageing, Health Future Institute, Murdoch University, Murdoch, Western Australia, Australia
| | - Mark P Molloy
- School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, New South Wales, Australia
- Australian Proteome Analysis Facility (APAF), Macquarie University, Sydney, New South Wales, Australia
- Bowel Cancer and Biomarker Research Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia
| | - David Ames
- National Ageing Research Institute, Parkville, Victoria, Australia
- Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, Victoria, Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
- Cogstate Ltd., Melbourne, Victoria, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Ralph N Martins
- Macquarie Medical School, Macquarie University, North Ryde, New South Wales, Australia
- School of Medical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
- Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia
- School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Western Australia, Australia
| |
Collapse
|
7
|
Mortlock S, Lord A, Montgomery G, Zakrzewski M, Simms LA, Krishnaprasad K, Hanigan K, Doecke JD, Walsh A, Lawrance IC, Bampton PA, Andrews JM, Mahy G, Connor SJ, Sparrow MP, Bell S, Florin TH, Begun J, Gearry RB, Radford-Smith GL. An Extremes of Phenotype Approach Confirms Significant Genetic Heterogeneity in Patients with Ulcerative Colitis. J Crohns Colitis 2023; 17:277-288. [PMID: 36111848 PMCID: PMC10024548 DOI: 10.1093/ecco-jcc/jjac121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Indexed: 02/08/2023]
Abstract
BACKGROUND AND AIMS Ulcerative colitis [UC] is a major form of inflammatory bowel disease globally. Phenotypic heterogeneity is defined by several variables including age of onset and disease extent. The genetics of disease severity remains poorly understood. To further investigate this, we performed a genome wide association [GWA] study using an extremes of phenotype strategy. METHODS We conducted GWA analyses in 311 patients with medically refractory UC [MRUC], 287 with non-medically refractory UC [non-MRUC] and 583 controls. Odds ratios [ORs] were calculated for known risk variants comparing MRUC and non-MRUC, and controls. RESULTS MRUC-control analysis had the greatest yield of genome-wide significant single nucleotide polymorphisms [SNPs] [2018], including lead SNP = rs111838972 [OR = 1.82, p = 6.28 × 10-9] near MMEL1 and a locus in the human leukocyte antigen [HLA] region [lead SNP = rs144717024, OR = 12.23, p = 1.7 × 10-19]. ORs for the lead SNPs were significantly higher in MRUC compared to non-MRUC [p < 9.0 × 10-6]. No SNPs reached significance in the non-MRUC-control analysis (top SNP, rs7680780 [OR 2.70, p = 5.56 × 10-8). We replicate findings for rs4151651 in the Complement Factor B [CFB] gene and demonstrate significant changes in CFB gene expression in active UC. Detailed HLA analyses support the strong associations with MHC II genes, particularly HLA-DQA1, HLA-DQB1 and HLA-DRB1 in MRUC. CONCLUSIONS Our MRUC subgroup replicates multiple known UC risk variants in contrast to non-MRUC and demonstrates significant differences in effect sizes compared to those published. Non-MRUC cases demonstrate lower ORs similar to those published. Additional risk and prognostic loci may be identified by targeted recruitment of individuals with severe disease.
Collapse
Affiliation(s)
- Sally Mortlock
- Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia
| | - Anton Lord
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
- Centre for Health Services Research, University of Queensland, Brisbane, QLD, Australia
| | - Grant Montgomery
- Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia
| | | | - Lisa A Simms
- QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
| | | | | | - James D Doecke
- Australian eHealth Research Centre, CSIRO, Brisbane, QLD, Australia
| | - Alissa Walsh
- Department of Gastroenterology, John Radcliffe Hospital, Headington, Oxford, UK
| | - Ian C Lawrance
- Centre of Inflammatory Bowel Diseases, Saint John of God Hospital Subiaco, University of Western Australia, WA, Australia
| | | | - Jane M Andrews
- Department of Gastroenterology and Hepatology, Royal Adelaide Hospital & University of Adelaide, Adelaide, SA, Australia
| | - Gillian Mahy
- Department of Gastroenterology and Hepatology, Townsville University Hospital, Townsville, QLD, Australia
| | - Susan J Connor
- Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, NSW, Australia
- South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia
| | - Miles P Sparrow
- Department of Gastroenterology, Alfred Health, Melbourne, VIC, Australia
| | - Sally Bell
- Department of Gastroenterology and Hepatology, Monash Health, Melbourne, VIC, Australia
| | - Timothy H Florin
- Inflammatory Bowel Diseases Group, Translational Research Institute, Brisbane, QLD, Australia
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
| | - Jakob Begun
- Inflammatory Bowel Diseases Group, Translational Research Institute, Brisbane, QLD, Australia
- Inflammatory Disease Biology and Therapeutics Group, Translational Research Institute, Brisbane, QLD, Australia
- Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
| | - Richard B Gearry
- Department of Medicine, University of Otago, Christchurch, New Zealand
| | - Graham L Radford-Smith
- Corresponding author: Graham Radford-Smith, Gut Health Lab, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. Tel: +617 3362 0499; Fax: +617 3009 0053;
| |
Collapse
|
8
|
Senesi M, Lewis V, Varghese S, Stehmann C, McGlade A, Doecke JD, Ellett L, Sarros S, Fowler CJ, Masters CL, Li QX, Collins SJ. Diagnostic performance of CSF biomarkers in a well-characterized Australian cohort of sporadic Creutzfeldt-Jakob disease. Front Neurol 2023; 14:1072952. [PMID: 36846121 PMCID: PMC9944944 DOI: 10.3389/fneur.2023.1072952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Accepted: 01/04/2023] [Indexed: 02/11/2023] Open
Abstract
The most frequently utilized biomarkers to support a pre-mortem clinical diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) include concentrations of the 14-3-3 and total tau (T-tau) proteins, as well as the application of protein amplification techniques, such as the real time quaking-induced conversion (RT-QuIC) assay, in cerebrospinal fluid (CSF). Utilizing CSF from a cohort of neuropathologically confirmed (definite) sCJD (n = 50) and non-CJD controls (n = 48), we established the optimal cutpoints for the fully automated Roche Elecsys® immunoassay for T-tau and the CircuLexTM 14-3-3 Gamma ELISA and compared these to T-tau protein measured using a commercially available assay (INNOTEST hTAU Ag) and 14-3-3 protein detection by western immunoblot (WB). These CSF specimens were also assessed for presence of misfolded prion protein using the RT-QuIC assay. T-tau showed similar diagnostic performance irrespective of the assay utilized, with ~90% sensitivity and specificity. The 14-3-3 protein detection by western blot (WB) has 87.5% sensitivity and 66.7% specificity. The 14-3-3 ELISA demonstrated 81.3% sensitivity and 84.4% specificity. RT-QuIC was the single best performing assay, with a sensitivity of 92.7% and 100% specificity. Our study indicates that a combination of all three CSF biomarkers increases sensitivity and offers the best chance of case detection pre-mortem. Only a single sCJD case in our cohort was negative across the three biomarkers, emphasizing the value of autopsy brain examination on all suspected CJD cases to ensure maximal case ascertainment.
Collapse
Affiliation(s)
- Matteo Senesi
- Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia,Department of Medicine, Royal Melbourne Hospital (RMH), The University of Melbourne, Parkville, VIC, Australia
| | - Victoria Lewis
- Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia,Department of Medicine, Royal Melbourne Hospital (RMH), The University of Melbourne, Parkville, VIC, Australia
| | - Shiji Varghese
- National Dementia Diagnostics Laboratory (NDDL), The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Christiane Stehmann
- Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Amelia McGlade
- Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | | | - Laura Ellett
- Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Shannon Sarros
- Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Christopher J. Fowler
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Colin L. Masters
- Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia,National Dementia Diagnostics Laboratory (NDDL), The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia,The Florey Institute of Neuroscience and Mental Health, Florey Department, The University of Melbourne, Parkville, VIC, Australia
| | - Qiao-Xin Li
- Department of Medicine, Royal Melbourne Hospital (RMH), The University of Melbourne, Parkville, VIC, Australia,The Florey Institute of Neuroscience and Mental Health, Florey Department, The University of Melbourne, Parkville, VIC, Australia,Qiao-Xin Li ✉
| | - Steven J. Collins
- Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR), The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia,Department of Medicine, Royal Melbourne Hospital (RMH), The University of Melbourne, Parkville, VIC, Australia,National Dementia Diagnostics Laboratory (NDDL), The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia,*Correspondence: Steven J. Collins ✉
| |
Collapse
|
9
|
Feizpour A, Doré V, Doecke JD, Saad ZS, Triana-Baltzer G, Slemmon R, Maruff P, Krishnadas N, Bourgeat P, Huang K, Fowler C, Rainey-Smith SR, Bush AI, Ward L, Robertson J, Martins RN, Masters CL, Villemagne VL, Fripp J, Kolb HC, Rowe CC. Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer's Continuum. J Prev Alzheimers Dis 2023; 10:828-836. [PMID: 37874105 DOI: 10.14283/jpad.2023.83] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2023]
Abstract
BACKGROUND Plasma p217+tau has shown high concordance with cerebrospinal fluid (CSF) and positron emission tomography (PET) measures of amyloid-β (Aβ) and tau in Alzheimer's Disease (AD). However, its association with longitudinal cognition and comparative performance to PET Aβ and tau in predicting cognitive decline are unknown. OBJECTIVES To evaluate whether p217+tau can predict the rate of cognitive decline observed over two-year average follow-up and compare this to prediction based on Aβ (18F-NAV4694) and tau (18F-MK6240) PET. We also explored the sample size required to detect a 30% slowing in cognitive decline in a 2-year trial and selection test cost using p217+tau (pT+) as compared to PET Aβ (A+) and tau (T+) with and without p217+tau pre-screening. DESIGN A prospective observational cohort study. SETTING Participants of the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) and Australian Dementia Network (ADNeT). PARTICIPANTS 153 cognitively unimpaired (CU) and 50 cognitively impaired (CI) individuals. MEASUREMENTS Baseline p217+tau Simoa® assay, 18F-MK6240 tau-PET and 18F-NAV4694 Aβ-PET with neuropsychological follow-up (MMSE, CDR-SB, AIBL-PACC) over 2.4 ± 0.8 years. RESULTS In CI, p217+tau was a significant predictor of change in MMSE (β = -0.55, p < 0.001) and CDR-SB (β =0.61, p < 0.001) with an effect size similar to Aβ Centiloid (MMSE β = -0.48, p = 0.002; CDR-SB β = 0.43, p = 0.004) and meta-temporal (MetaT) tau SUVR (MMSE: β = -0.62, p < 0.001; CDR-SB: β = 0.65, p < 0.001). In CU, only MetaT tau SUVR was significantly associated with change in AIBL-PACC (β = -0.22, p = 0.008). Screening pT+ CI participants into a trial could lead to 24% reduction in sample size compared to screening with PET for A+ and 6-13% compared to screening with PET for T+ (different regions). This would translate to an 81-83% biomarker test cost-saving assuming the p217+tau test cost one-fifth of a PET scan. In a trial requiring PET A+ or T+, p217+tau pre-screening followed by PET in those who were pT+ would cost more in the CI group, compared to 26-38% biomarker test cost-saving in the CU. CONCLUSIONS Substantial cost reduction can be achieved using p217+tau alone to select participants with MCI or mild dementia for a clinical trial designed to slow cognitive decline over two years, compared to participant selection by PET. In pre-clinical AD trials, p217+tau provides significant cost-saving if used as a pre-screening measure for PET A+ or T+ but in MCI/mild dementia trials this may add to cost both in testing and in the increased number of participants needed for testing.
Collapse
Affiliation(s)
- A Feizpour
- Professor Christopher C Rowe, Department of Molecular Imaging and Therapy, Austin Health, 145 Studley Road, Heidelberg, VIC. 3084, Australia. Telephone: +61-3-9496 3321. Fax +61-3-9458 5023.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Huang L, Long JP, Irajizad E, Doecke JD, Do KA, Ha MJ. A unified mediation analysis framework for integrative cancer proteogenomics with clinical outcomes. Bioinformatics 2023; 39:6989623. [PMID: 36648331 PMCID: PMC9879726 DOI: 10.1093/bioinformatics/btad023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2022] [Revised: 11/18/2022] [Accepted: 01/16/2023] [Indexed: 01/18/2023] Open
Abstract
MOTIVATION Multilevel molecular profiling of tumors and the integrative analysis with clinical outcomes have enabled a deeper characterization of cancer treatment. Mediation analysis has emerged as a promising statistical tool to identify and quantify the intermediate mechanisms by which a gene affects an outcome. However, existing methods lack a unified approach to handle various types of outcome variables, making them unsuitable for high-throughput molecular profiling data with highly interconnected variables. RESULTS We develop a general mediation analysis framework for proteogenomic data that include multiple exposures, multivariate mediators on various scales of effects as appropriate for continuous, binary and survival outcomes. Our estimation method avoids imposing constraints on model parameters such as the rare disease assumption, while accommodating multiple exposures and high-dimensional mediators. We compare our approach to other methods in extensive simulation studies at a range of sample sizes, disease prevalence and number of false mediators. Using kidney renal clear cell carcinoma proteogenomic data, we identify genes that are mediated by proteins and the underlying mechanisms on various survival outcomes that capture short- and long-term disease-specific clinical characteristics. AVAILABILITY AND IMPLEMENTATION Software is made available in an R package (https://github.com/longjp/mediateR). SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.
Collapse
Affiliation(s)
- Licai Huang
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Ehsan Irajizad
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - James D Doecke
- CSIRO, Royal Brisbane and Women’s Hospital, Brisbane, Australia
| | - Kim-Anh Do
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Min Jin Ha
- To whom correspondence should be addressed.
| |
Collapse
|
11
|
Gillis C, Cespedes MI, Maserejian NN, Dore V, Maruff P, Fowler C, Rainey‐Smith S, Villemagne VL, Rowe C, Martins RN, Vacher M, Masters CL, Doecke JD. Alzheimer’s disease specific MRI brain regions are differentially associated with accelerated decline as defined using sigmoidal cognitive turning point methodology in amyloid‐positive AIBL participants. Alzheimers Dement 2022. [DOI: 10.1002/alz.064503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | | | - Vincent Dore
- Australian E‐Health Research Centre, CSIRO Parkville VIC Australia
| | - Paul Maruff
- Cogstate Pty. Ltd New Haven CT USA
- University of Melbourne Melbourne VIC Australia
| | - Christopher Fowler
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Stephanie Rainey‐Smith
- Centre for Healthy Ageing, Murdoch University Perth Western Australia Australia
- Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University Joondalup Western Australia Australia
| | - Victor L Villemagne
- Department of Molecular Imaging and Therapy, Austin Health Heidelberg VIC Australia
- Department of Psychiatry, University of Pittsburgh Pittsburgh PA USA
| | - Christopher Rowe
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
- Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University Sydney NSW Australia
| | - Ralph N Martins
- Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University Joondalup Western Australia Australia
- Department of Biomedical Sciences, Faculty of Medicine, Health and Human Sciences, Macquarie University Sydney NSW Australia
- Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) Perth Western Australia Australia
| | - Michael Vacher
- Australian E‐Health Research Centre, CSIRO Perth Western Australia Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne Parkville VIC Australia
| | - James D Doecke
- Australian E‐Health Research Centre, CSIRO Herston QLD Australia
| |
Collapse
|
12
|
Cox T, Bourgeat P, Dore V, Doecke JD, Fripp J, Chatterjee P, Schindler EE, Benzinger TL, Rowe C, Villemagne VL, Weiner MW, Morris JC, Masters CL. Comparing the longitudinal progression of CSF biomarkers with PET Amyloid biomarkers for Alzheimer’s disease. Alzheimers Dement 2022. [DOI: 10.1002/alz.068082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Timothy Cox
- The Australian e‐Health Research Centre, CSIRO Canberra ACT Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Vincent Dore
- Department of Molecular Imaging & Therapy, Austin Health Heidelberg VIC Australia
- Australian E‐Health Research Centre, CSIRO Parkville VIC Australia
| | - James D Doecke
- Australian E‐Health Research Centre, CSIRO Herston QLD Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | | | | | | | - Christopher Rowe
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
- The University of Melbourne Melbourne VIC Australia
| | | | | | - John C. Morris
- Washington University School of Medicine St. Louis MO USA
| | - Colin L. Masters
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
- The University of Melbourne Melbourne VIC Australia
| |
Collapse
|
13
|
Piccirella S, Van Neste L, Fowler C, Masters CL, Fripp J, Doecke JD, Xiong C, Uberti D, Kinnon P. AlzoSure® Predict, a simple minimally‐invasive blood test to predict the early onset of Alzheimer’s disease before the manifestation of clinical symptoms. Alzheimers Dement 2022. [DOI: 10.1002/alz.069262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | | | - Christopher Fowler
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne Parkville VIC Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - James D Doecke
- Australian E‐Health Research Centre, CSIRO Herston QLD Australia
| | - Chengjie Xiong
- Washington University School of Medicine Saint Louis MO USA
| | - Daniela Uberti
- Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli Brescia Italy
| | | |
Collapse
|
14
|
Pivac LN, Brown BM, Sewell KR, Doecke JD, Villemagne VL, Dore V, Weinborn M, Sohrabi HR, Gardener SL, Bucks RS, Masters CL, Rowe C, Martins RN, Rainey‐Smith S. Suboptimal sleep efficiency and duration predicts rate of accumulation of Aβ‐ Amyloid in cognitively normal older adults. Alzheimers Dement 2022. [DOI: 10.1002/alz.060975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
| | - Belinda M Brown
- Centre for Healthy Ageing, Murdoch University Perth Western Australia Australia
- Australian Alzheimer's Research Foundation Perth Western Australia Australia
| | | | - James D Doecke
- Australian E‐Health Research Centre, CSIRO Herston QLD Australia
| | | | - Vincent Dore
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
| | - Michael Weinborn
- University of Western Australia Perth Western Australia Australia
| | - Hamid R Sohrabi
- Australian Alzheimer's Research Foundation Perth Western Australia Australia
- Centre for Healthy Ageing, Murdoch University Murdoch Western Australia Australia
| | | | - Romola S Bucks
- University of Western Australia Perth Western Australia Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne Melbourne VIC Australia
| | - Christopher Rowe
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Ralph N Martins
- Edith Cowan University Joondalup Western Australia Australia
| | - Stephanie Rainey‐Smith
- Centre for Healthy Ageing, Murdoch University Perth Western Australia Australia
- Australian Alzheimer's Research Foundation Perth Western Australia Australia
| |
Collapse
|
15
|
Fowler C, Stoops E, Rainey‐Smith S, Vanmechelen E, Vanbrabant J, Dewit N, Mauroo K, Rowe C, Fripp J, Li Q, Bourgeat P, Collins S, Martins RN, Masters CL, Maruff P, Doecke JD. Plasma pTau181/Aβ42 identifies cognitive change earlier than CSF pTau181/Ab42. Alzheimers Dement 2022. [DOI: 10.1002/alz.064341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Affiliation(s)
- Christopher Fowler
- Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Erik Stoops
- ADx NeuroSciences NV, Technologiepark 94 Ghent 9052 Belgium
| | - Stephanie Rainey‐Smith
- Murdoch University, Murdoch Western Australia Australia
- Australian Alzheimer's Research Foundation Perth Western Australia Australia
- Ageing, Cognition and Exercise Research Group Murdoch Australia
| | - Eugeen Vanmechelen
- ADx NeuroSciences NV, Technologiepark 94 Ghent 9052 Belgium
- ADx NeuroSciences Ghent Belgium
| | | | | | | | - Christopher Rowe
- Departments of Medicine and Molecular Imaging, University of Melbourne Health, Austin Melbourne VIC Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Qiao‐Xin Li
- The Florey Institute of Neuroscience, University of Melbourne PARKVILLE VIC Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Steven Collins
- National Dementia Diagnostics Laboratory, The Florey Institute of Neuroscience and Mental Health Parkville VIC Australia
| | - Ralph N Martins
- KaRa Institute of Neurological Diseases Sydney NSW Australia
- Australian Alzheimer's Research Foundation Nedlands Australia
- Edith Cowan University, Joondalup Western Australia Australia
- Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) Perth Western Australia Australia
- Department of Biomedical Sciences, Macquarie University Macquarie Park NSW Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne Melbourne VIC Australia
| | - Paul Maruff
- Cogstate Ltd. Melbourne VIC Australia
- The Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
| | - James D Doecke
- Australian E‐Health Research Centre, CSIRO Herston QLD Australia
| |
Collapse
|
16
|
McNicholas K, François M, Liu JW, Doecke JD, Hecker J, Faunt J, Maddison J, Johns S, Pukala TL, Rush RA, Leifert WR. Salivary inflammatory biomarkers are predictive of mild cognitive impairment and Alzheimer's disease in a feasibility study. Front Aging Neurosci 2022; 14:1019296. [PMID: 36438010 PMCID: PMC9685799 DOI: 10.3389/fnagi.2022.1019296] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2022] [Accepted: 10/26/2022] [Indexed: 09/10/2023] Open
Abstract
Alzheimer's disease (AD) is an insidious disease. Its distinctive pathology forms over a considerable length of time without symptoms. There is a need to detect this disease, before even subtle changes occur in cognition. Hallmark AD biomarkers, tau and amyloid-β, have shown promising results in CSF and blood. However, detecting early changes in these biomarkers and others will involve screening a wide group of healthy, asymptomatic individuals. Saliva is a feasible alternative. Sample collection is economical, non-invasive and saliva is an abundant source of proteins including tau and amyloid-β. This work sought to extend an earlier promising untargeted mass spectrometry study in saliva from individuals with mild cognitive impairment (MCI) or AD with age- and gender-matched cognitively normal from the South Australian Neurodegenerative Disease cohort. Five proteins, with key roles in inflammation, were chosen from this study and measured by ELISA from individuals with AD (n = 16), MCI (n = 15) and cognitively normal (n = 29). The concentrations of Cystatin-C, Interleukin-1 receptor antagonist, Stratifin, Matrix metalloproteinase 9 and Haptoglobin proteins had altered abundance in saliva from AD and MCI, consistent with the earlier study. Receiver operating characteristic analysis showed that combinations of these proteins demonstrated excellent diagnostic accuracy for distinguishing both MCI (area under curve = 0.97) and AD (area under curve = 0.97) from cognitively normal. These results provide evidence for saliva being a valuable source of biomarkers for early detection of cognitive impairment in individuals on the AD continuum and potentially other neurodegenerative diseases.
Collapse
Affiliation(s)
- Kym McNicholas
- Molecular Diagnostic Solutions Group, Human Health Program, CSIRO Health and Biosecurity, Adelaide, SA, Australia
- School of Biological Sciences, The University of Adelaide, Adelaide, SA, Australia
| | - Maxime François
- Molecular Diagnostic Solutions Group, Human Health Program, CSIRO Health and Biosecurity, Adelaide, SA, Australia
- School of Biological Sciences, The University of Adelaide, Adelaide, SA, Australia
| | - Jian-Wei Liu
- CSIRO Land and Water, Black Mountain Research and Innovation Park, Canberra, ACT, Australia
| | - James D. Doecke
- Australian e-Health Research Centre, CSIRO, Herston, QLD, Australia
| | - Jane Hecker
- Department of Internal Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - Jeff Faunt
- Department of General Medicine, Royal Adelaide Hospital, Adelaide, SA, Australia
| | - John Maddison
- Aged Care Rehabilitation and Palliative Care, SA Health, Modbury Hospital, Modbury, SA, Australia
| | - Sally Johns
- Aged Care Rehabilitation and Palliative Care, SA Health, Modbury Hospital, Modbury, SA, Australia
| | - Tara L. Pukala
- School of Physical Sciences, The University of Adelaide, Adelaide, SA, Australia
| | | | - Wayne R. Leifert
- Molecular Diagnostic Solutions Group, Human Health Program, CSIRO Health and Biosecurity, Adelaide, SA, Australia
- School of Biological Sciences, The University of Adelaide, Adelaide, SA, Australia
| |
Collapse
|
17
|
François M, Karpe AV, Liu JW, Beale DJ, Hor M, Hecker J, Faunt J, Maddison J, Johns S, Doecke JD, Rose S, Leifert WR. Multi-Omics, an Integrated Approach to Identify Novel Blood Biomarkers of Alzheimer's Disease. Metabolites 2022; 12:949. [PMID: 36295851 PMCID: PMC9610280 DOI: 10.3390/metabo12100949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Revised: 09/29/2022] [Accepted: 10/03/2022] [Indexed: 11/16/2022] Open
Abstract
The metabolomic and proteomic basis of mild cognitive impairment (MCI) and Alzheimer's disease (AD) is poorly understood, and the relationships between systemic abnormalities in metabolism and AD/MCI pathogenesis is unclear. This study compared the metabolomic and proteomic signature of plasma from cognitively normal (CN) and dementia patients diagnosed with MCI or AD, to identify specific cellular pathways and new biomarkers altered with the progression of the disease. We analysed 80 plasma samples from individuals with MCI or AD, as well as age- and gender-matched CN individuals, by utilising mass spectrometry methods and data analyses that included combined pathway analysis and model predictions. Several proteins clearly identified AD from the MCI and CN groups and included plasma actins, mannan-binding lectin serine protease 1, serum amyloid A2, fibronectin and extracellular matrix protein 1 and Keratin 9. The integrated pathway analysis showed various metabolic pathways were affected in AD, such as the arginine, alanine, aspartate, glutamate and pyruvate metabolism pathways. Therefore, our multi-omics approach identified novel plasma biomarkers for the MCI and AD groups, identified changes in metabolic processes, and may form the basis of a biomarker panel for stratifying dementia participants in future clinical trials.
Collapse
Affiliation(s)
- Maxime François
- CSIRO Health & Biosecurity, Human Health Program, Molecular Diagnostic Solutions Group, Adelaide, SA 5000, Australia
| | - Avinash V. Karpe
- CSIRO Land & Water, Metabolomics Unit, Ecosciences Precinct, Dutton Park, QLD 4001, Australia
| | - Jian-Wei Liu
- CSIRO Land & Water, Agricultural and Environmental Sciences Precinct, Acton, Canberra, ACT 2601, Australia
| | - David J. Beale
- CSIRO Land & Water, Metabolomics Unit, Ecosciences Precinct, Dutton Park, QLD 4001, Australia
| | - Maryam Hor
- CSIRO Health & Biosecurity, Human Health Program, Molecular Diagnostic Solutions Group, Adelaide, SA 5000, Australia
| | - Jane Hecker
- Department of Internal Medicine, Royal Adelaide Hospital, Adelaide, SA 5000, Australia
| | - Jeff Faunt
- Department of General Medicine, Royal Adelaide Hospital, Adelaide, SA 5000, Australia
| | - John Maddison
- Aged Care Rehabilitation & Palliative Care, SA Health, Modbury Hospital, Modbury, SA 5092, Australia
| | - Sally Johns
- Aged Care Rehabilitation & Palliative Care, SA Health, Modbury Hospital, Modbury, SA 5092, Australia
| | - James D. Doecke
- Australian e-Health Research Centre, CSIRO, Level 7, Surgical Treatment and Rehabilitation Service—STARS, Herston, QLD 4029, Australia
| | - Stephen Rose
- Australian e-Health Research Centre, CSIRO, Level 7, Surgical Treatment and Rehabilitation Service—STARS, Herston, QLD 4029, Australia
| | - Wayne R. Leifert
- CSIRO Health & Biosecurity, Human Health Program, Molecular Diagnostic Solutions Group, Adelaide, SA 5000, Australia
| |
Collapse
|
18
|
Pedrini S, Doecke JD, Hone E, Wang P, Thota R, Bush AI, Rowe CC, Dore V, Villemagne VL, Ames D, Rainey‐Smith S, Verdile G, Sohrabi HR, Raida MR, Taddei K, Gandy S, Masters CL, Chatterjee P, Martins R. Plasma high-density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume. J Neurochem 2022; 163:53-67. [PMID: 36000528 PMCID: PMC9804612 DOI: 10.1111/jnc.15681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2022] [Revised: 07/12/2022] [Accepted: 07/22/2022] [Indexed: 01/05/2023]
Abstract
Cholesterol levels have been repeatedly linked to Alzheimer's Disease (AD), suggesting that high levels could be detrimental, but this effect is likely attributed to Low-Density Lipoprotein (LDL) cholesterol. On the other hand, High-Density Lipoproteins (HDL) cholesterol levels have been associated with reduced brain amyloidosis and improved cognitive function. However, recent findings have suggested that HDL-functionality, which depends upon the HDL-cargo proteins associated with HDL, rather than HDL levels, appears to be the key factor, suggesting a quality over quantity status. In this report, we have assessed the HDL-cargo (Cholesterol, ApoA-I, ApoA-II, ApoC-I, ApoC-III, ApoD, ApoE, ApoH, ApoJ, CRP, and SAA) in stable healthy control (HC), healthy controls who will convert to MCI/AD (HC-Conv) and AD patients (AD). Compared to HC we observed an increased cholesterol/ApoA-I ratio in AD and HC-Conv, as well as an increased ApoD/ApoA-I ratio and a decreased ApoA-II/ApoA-I ratio in AD. Higher cholesterol/ApoA-I ratio was also associated with lower cortical grey matter volume and higher ventricular volume, while higher ApoA-II/ApoA-I and ApoJ/ApoA-I ratios were associated with greater cortical grey matter volume (and for ApoA-II also with greater hippocampal volume) and smaller ventricular volume. Additionally, in a clinical status-independent manner, the ApoE/ApoA-I ratio was significantly lower in APOE ε4 carriers and lowest in APOE ε4 homozygous. Together, these data indicate that in AD patients the composition of HDL is altered, which may affect HDL functionality, and such changes are associated with altered regional brain volumetric data.
Collapse
Affiliation(s)
- Steve Pedrini
- School of Medical SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia,CRC for Mental HealthMelbourneVictoriaAustralia
| | - James D. Doecke
- Australian E‐Health Research CentreCSIROBrisbaneQueenslandAustralia
| | - Eugene Hone
- School of Medical SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia,CRC for Mental HealthMelbourneVictoriaAustralia
| | - Penghao Wang
- College of Science, Health, Engineering and EducationMurdoch UniversityMurdochWestern AustraliaAustralia
| | - Rohith Thota
- Faculty of Medicine, Health and Human Sciences, Department of Biomedical SciencesMacquarie UniversitySydneyNew South WalesAustralia
| | - Ashley I. Bush
- CRC for Mental HealthMelbourneVictoriaAustralia,The Florey Institute, The University of MelbourneParkvilleVictoriaAustralia
| | - Christopher C. Rowe
- Department of Nuclear Medicine and Centre for PETAustin HealthHeidelbergVictoriaAustralia
| | - Vincent Dore
- Department of Nuclear Medicine and Centre for PETAustin HealthHeidelbergVictoriaAustralia
| | | | - David Ames
- National Ageing Research InstituteParkvilleVictoriaAustralia,University of Melbourne Academic unit for Psychiatry of Old AgeSt George's HospitalKewVictoriaAustralia
| | - Stephanie Rainey‐Smith
- School of Medical SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia,Centre for Healthy Ageing, Health Futures InstituteMurdoch UniversityMurdochWestern AustraliaAustralia
| | - Giuseppe Verdile
- Curtin Medical SchoolCurtin UniversityBentleyWestern AustraliaAustralia,Curtin Health Innovation Research InstituteCurtin UniversityBentleyWestern AustraliaAustralia
| | - Hamid R. Sohrabi
- Centre for Healthy Ageing, Health Futures InstituteMurdoch UniversityMurdochWestern AustraliaAustralia
| | - Manfred R. Raida
- Life Science Institute, Singapore Lipidomics IncubatorNational University of SingaporeSingapore CitySingapore
| | - Kevin Taddei
- School of Medical SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia,CRC for Mental HealthMelbourneVictoriaAustralia
| | - Sam Gandy
- Department of NeurologyIcahn School of Medicine at Mount SinaiNew York CityNew YorkUSA
| | - Colin L. Masters
- The Florey Institute, The University of MelbourneParkvilleVictoriaAustralia
| | - Pratishtha Chatterjee
- Faculty of Medicine, Health and Human Sciences, Department of Biomedical SciencesMacquarie UniversitySydneyNew South WalesAustralia
| | - Ralph N. Martins
- School of Medical SciencesEdith Cowan UniversityJoondalupWestern AustraliaAustralia,CRC for Mental HealthMelbourneVictoriaAustralia,Faculty of Medicine, Health and Human Sciences, Department of Biomedical SciencesMacquarie UniversitySydneyNew South WalesAustralia,School of Psychiatry and Clinical NeurosciencesUniversity of Western AustraliaCrawleyWestern AustraliaAustralia
| | | |
Collapse
|
19
|
Piccirella S, Van Neste L, Fowler C, Masters CL, Fripp J, Doecke JD, Xiong C, Uberti D, Kinnon P. A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease. J Prev Alzheimers Dis 2022; 9:469-479. [PMID: 35841248 DOI: 10.14283/jpad.2022.52] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND Ongoing research seeks to identify blood-based biomarkers able to predict onset and progression of Alzheimer's disease (AD). OBJECTIVE The unfolded conformational variant of p53 (U-p53AZ), previously observed in AD individuals, was evaluated in plasma samples from individuals participating in the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort for diagnostic and prognostic assessment, validated on a neuropsychological-based diagnosis, over the course of six years. DESIGN Retrospective Longitudinal Prognostic biomarker study. SETTING Single-center study based on the AIBL cohort. PARTICIPANTS 482 participants of the AIBL cohort, aged 60-85 years, without uncontrolled diabetes, vascular disease, severe depression or psychiatric illnesses. MEASUREMENTS The AlzoSure® Predict test, consisting of immunoprecipitation (IP) followed by liquid chromatography (LC) tandem mass spectrometry (MS/MS), was performed to quantify the AZ 284® peptide as readout of U-p53AZ and compared with an independent neuropsychological diagnosis. The amyloid load via amyloid β-positron emission tomography (Aβ-PET) and supporting clinical information were included where possible. RESULTS U-p53AZ diagnostic and prognostic performance was assessed in both time-independent and time-dependent (36, 72 and 90 months following initial sampling) analyses. Prognostic performance of Aβ-PET and survival analyses with different risk factors (gender, Aβ-PET and APOE ε4 allele status) were also performed. U-p53AZ differentiated neuropsychologically graded AD from non-AD samples, and its detection at intermediate/high levels precisely identified present and future symptomatic AD. In both time-independent and time-dependent prognostic analyses U-p53AZ achieved area under the curve (AUC) >98%, significantly higher than Aβ-PET AUCs (between 84% and 93%, P respectively <0.0001 and <0.001). As single factor, U-p53AZ could clearly determine the risk of AD neuropsychological diagnosis over time (low versus intermediate/high U-p53AZ hazard ratio=2.99). Proportional hazards regression analysis identified U-p53AZ levels as a major independent predictor of AD onset. CONCLUSIONS These findings support use of U-p53AZ as blood-based biomarker predicting whether individuals would reach neuropsychologically-defined AD within six years prior to AD diagnosis. Integration of U-p53AZ in screening processes could support refined participant stratification for interventional studies.
Collapse
|
20
|
Li Y, Huang X, Fowler C, Lim YY, Laws SM, Faux N, Doecke JD, Trounson B, Pertile K, Rumble R, Doré V, Villemagne VL, Rowe CC, Wiley JS, Maruff P, Masters CL, Gu BJ. Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease. Int J Mol Sci 2022; 23:ijms23147867. [PMID: 35887215 PMCID: PMC9322488 DOI: 10.3390/ijms23147867] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 07/10/2022] [Accepted: 07/12/2022] [Indexed: 02/04/2023] Open
Abstract
Alzheimer's disease (AD) has shown altered immune responses in the periphery. We studied P2X7 (a proinflammatory receptor and a scavenger receptor) and two integrins, CD11b and CD11c, on the surface of circulating leukocytes and analysed their associations with Aβ-PET, brain atrophy, neuropsychological assessments, and cerebrospinal fluid (CSF) biomarkers. Total 287 age-matched, sex-balanced participants were recruited in a discovery cohort and two validation cohorts through the AIBL study and studied using tri-colour flow cytometry. Our results demonstrated reduced expressions of P2X7, CD11b, and CD11c on leukocytes, particularly monocytes, in Aβ +ve cases compared with Aβ -ve controls. P2X7 and integrin downregulation was observed at pre-clinical stage of AD and stayed low throughout disease course. We further constructed a polygenic risk score (PRS) model based on 12 P2RX7 risk alleles to assess the genetic impact on P2X7 function in AIBL and ADNI cohorts. No significant association was identified between the P2RX7 gene and AD, indicating that P2X7 downregulation in AD is likely caused by environmental changes rather than genetic factors. In conclusion, the downregulation of P2X7 and integrins at pre-clinical stage of AD indicates altered pro-inflammatory responses, phagocytic functions, and migrating capabilities of circulating monocytes in early AD pathogenesis. Our study not only improves our understanding of peripheral immune involvement in early stage of AD but also provides more insights into novel biomarker development, diagnosis, and prognosis of AD.
Collapse
Affiliation(s)
- Yihan Li
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Xin Huang
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Christopher Fowler
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Yen Y. Lim
- School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC 3168, Australia; (Y.Y.L.); (V.D.)
| | - Simon M. Laws
- School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia;
| | - Noel Faux
- Melbourne Data Analytics Platform, Petascale Campus Initiative, The University of Melbourne, 21 Bedford St., North Melbourne, VIC 3051, Australia;
| | - James D. Doecke
- The Australian e-Health Research Centre, CSIRO, Brisbane, QLD 4029, Australia;
| | - Brett Trounson
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Kelly Pertile
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Rebecca Rumble
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Vincent Doré
- School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC 3168, Australia; (Y.Y.L.); (V.D.)
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC 3084, Australia; (V.L.V.); (C.C.R.)
- Department of Medicine, The University of Melbourne, Melbourne, VIC 3084, Australia
| | - Victor L. Villemagne
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC 3084, Australia; (V.L.V.); (C.C.R.)
- Department of Medicine, The University of Melbourne, Melbourne, VIC 3084, Australia
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Christopher C. Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC 3084, Australia; (V.L.V.); (C.C.R.)
- Department of Medicine, The University of Melbourne, Melbourne, VIC 3084, Australia
| | - James S. Wiley
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Paul Maruff
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
- CogState Ltd., Melbourne, VIC 3001, Australia
| | - Colin L. Masters
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Ben J. Gu
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
- Correspondence: ; Tel.: +61-3-9035-6317
| |
Collapse
|
21
|
Cespedes M, Jacobs KR, Maruff P, Rembach A, Fowler CJ, Trounson B, Pertile KK, Rumble RL, Rainey-Smithe SR, Rowe CC, Villemagne VL, Bourgeat P, Lim CK, Chatterjee P, Martins RN, Ittner A, Masters CL, Doecke JD, Guillemin GJ, Lovejoy DB. Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β. Neurobiol Dis 2022; 171:105783. [DOI: 10.1016/j.nbd.2022.105783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2021] [Revised: 05/30/2022] [Accepted: 06/01/2022] [Indexed: 11/16/2022] Open
|
22
|
Vacher M, Doré V, Porter T, Milicic L, Villemagne VL, Bourgeat P, Burnham SC, Cox T, Masters CL, Rowe CC, Fripp J, Doecke JD, Laws SM. Assessment of a polygenic hazard score for the onset of pre-clinical Alzheimer's disease. BMC Genomics 2022; 23:401. [PMID: 35619096 PMCID: PMC9134703 DOI: 10.1186/s12864-022-08617-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Accepted: 05/09/2022] [Indexed: 11/29/2022] Open
Abstract
Abstract Background With a growing number of loci associated with late-onset (sporadic) Alzheimer’s disease (AD), the polygenic contribution to AD is now well established. The development of polygenic risk score approaches have shown promising results for identifying individuals at higher risk of developing AD, thereby facilitating the development of preventative and therapeutic strategies. A polygenic hazard score (PHS) has been proposed to quantify age-specific genetic risk for AD. In this study, we assessed the predictive power and transferability of this PHS in an independent cohort, to support its clinical utility. Results Using genotype and imaging data from 780 individuals enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study, we investigated associations between the PHS and several AD-related traits, including 1) cross-sectional Aβ-amyloid (Aβ) deposition, 2) longitudinal brain atrophy, 3) longitudinal cognitive decline, 4) age of onset. Except in the cognitive domain, we obtained results that were consistent with previously published findings. The PHS was associated with increased Aβ burden, faster regional brain atrophy and an earlier age of onset. Conclusion Overall, the results support the predictive power of a PHS, however, with only marginal improvement compared to apolipoprotein E alone. Supplementary Information The online version contains supplementary material available at 10.1186/s12864-022-08617-2.
Collapse
Affiliation(s)
- Michael Vacher
- Australian e-Health Research Centre, CSIRO, Floreat, Western Australia, 6014, Australia. .,Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia. .,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, 6027, Western Australia.
| | - Vincent Doré
- Australian e-Health Research Centre, CSIRO, Parkville, Victoria, 3052, Australia.,Department of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Tenielle Porter
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, 6027, Western Australia.,Curtin Health Innovation Research Institute, Curtin University, Bentley, 6102, Western Australia
| | - Lidija Milicic
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, 6027, Western Australia
| | - Victor L Villemagne
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
| | - Pierrick Bourgeat
- Australian e-Health Research Centre, CSIRO, Herston, Queensland, 4029, Australia
| | - Sam C Burnham
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Australian e-Health Research Centre, CSIRO, Parkville, Victoria, 3052, Australia
| | - Timothy Cox
- Australian e-Health Research Centre, CSIRO, Parkville, Victoria, 3052, Australia
| | - Colin L Masters
- Florey Institute, The University of Melbourne, Parkville, VIC, 3052, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Jurgen Fripp
- Australian e-Health Research Centre, CSIRO, Herston, Queensland, 4029, Australia
| | - James D Doecke
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Australian e-Health Research Centre, CSIRO, Herston, Queensland, 4029, Australia
| | - Simon M Laws
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, 6027, Australia.,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, 6027, Western Australia.,Curtin Health Innovation Research Institute, Curtin University, Bentley, 6102, Western Australia
| |
Collapse
|
23
|
Vacher M, Porter T, Milicic L, Bourgeat P, Dore V, Villemagne VL, Laws SM, Doecke JD. A Targeted Association Study of Blood-Brain Barrier Gene SNPs and Brain Atrophy. J Alzheimers Dis 2022; 86:1817-1829. [DOI: 10.3233/jad-210644] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background: The blood-brain barrier (BBB) is formed by a high-density lining of endothelial cells, providing a border between circulating blood and the brain interstitial fluid. This structure plays a key role in protecting the brain microenvironment by restricting passage of certain molecules and circulating pathogens. Objective: To identify associations between brain volumetric changes and a set of 355 BBB-related single nucleotide polymorphisms (SNP). Method: In a population of 721 unrelated individuals, linear mixed effect models were used to assess if specific variants were linked to regional rates of atrophy over a 12-year time span. Four brain regions were investigated, including cortical grey matter, cortical white matter, ventricle, and hippocampus. Further, we also investigated the potential impact of history of hypertension, diabetes, and the incidence of stroke on regional brain volume change. Results: History of hypertension, diabetes, and stroke was not associated with longitudinal brain volume change. However, we identified a series of genetic variants associated with regional brain volume changes. The associations were independent of variation due to the APOEɛ4 allele and were significant post correction for multiple comparisons. Conclusion: This study suggests that key genes involved in the regulation of BBB integrity may be associated with longitudinal changes in specific brain regions. The derived polygenic risk scores indicate that these interactions are multigenic. Further research needs to be conducted to investigate how BBB functions maybe compromised by genetic variation.
Collapse
Affiliation(s)
- Michael Vacher
- CSIRO Health and Biosecurity, Australian e-Health Research Centre, Floreat, Western Australia, Australia
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia
| | - Tenielle Porter
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia
| | - Lidija Milicic
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity, Australian e-Health Research Centre, Herston, Queensland, Australia
| | - Vincent Dore
- CSIRO Health and Biosecurity, Australian e-Health Research Centre, Herston, Queensland, Australia
| | - Victor L Villemagne
- Department of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
| | - Simon M. Laws
- Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia
- Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia
- School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia
| | - James D. Doecke
- CSIRO Health and Biosecurity, Australian e-Health Research Centre, Herston, Queensland, Australia
| |
Collapse
|
24
|
Laffoon SB, Doecke JD, Roberts AM, Vance JA, Reeves BD, Pertile KK, Rumble RL, Fowler CJ, Trounson B, Ames D, Martins R, Bush AI, Masters CL, Grieco PA, Dratz EA, Roberts BR. Analysis of plasma proteins using 2D gels and novel fluorescent probes: in search of blood based biomarkers for Alzheimer's disease. Proteome Sci 2022; 20:2. [PMID: 35081972 PMCID: PMC8790928 DOI: 10.1186/s12953-021-00185-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Accepted: 12/23/2021] [Indexed: 11/16/2022] Open
Abstract
Background The Australian Imaging and Biomarker Lifestyle (AIBL) study of aging is designed to aid the discovery of biomarkers. The current study aimed to discover differentially expressed plasma proteins that could yield a blood-based screening tool for Alzheimer’s disease. Methods The concentration of proteins in plasma covers a vast range of 12 orders of magnitude. Therefore, to search for medium to low abundant biomarkers and elucidate mechanisms of AD, we immuno-depleted the most abundant plasma proteins and pre-fractionated the remaining proteins by HPLC, prior to two-dimensional gel electrophoresis. The relative levels of approximately 3400 protein species resolved on the 2D gels were compared using in-gel differential analysis with spectrally resolved fluorescent protein detection dyes (Zdyes™). Here we report on analysis of pooled plasma samples from an initial screen of a sex-matched cohort of 72 probable AD patients and 72 healthy controls from the baseline time point of AIBL. Results We report significant changes in variants of apolipoprotein E, haptoglobin, α1 anti-trypsin, inter-α trypsin inhibitor, histidine-rich glycoprotein, and a protein of unknown identity. α1 anti-trypsin and α1 anti-chymotrypsin demonstrated plasma concentrations that were dependent on APOE ε4 allele dose. Our analysis also identified an association with the level of Vitamin D binding protein fragments and complement factor I with sex. We then conducted a preliminary validation study, on unique individual samples compared to the discovery cohort, using a targeted LC-MS/MS assay on a subset of discovered biomarkers. We found that targets that displayed a high degree of isoform specific changes in the 2D gels were not changed in the targeted MS assay which reports on the total level of the biomarker. Conclusions This demonstrates that further development of mass spectrometry assays is needed to capture the isoform complexity that exists in theses biological samples. However, this study indicates that a peripheral protein signature has potential to aid in the characterization of AD. Supplementary Information The online version contains supplementary material available at 10.1186/s12953-021-00185-9.
Collapse
Affiliation(s)
- Scott B Laffoon
- Florey Institute of Neuroscience and Mental Health and The University of Melbourne Dementia Research Centre, Parkville, VIC, 3010, Australia.,Department of Chemistry and Biochemistry, Montana State University, Bozeman, MT, 59715, USA.,Cooperative Research Centre for Mental Health, Carlton South, VIC, Australia
| | - James D Doecke
- Australian e-Health Research Centre, CSIRO and Cooperative Research Centre of Mental Health, Royal Brisbane and Women's Hospital, Brisbane, QLD, 4029, Australia
| | - Anne M Roberts
- Department of Biochemistry, Emory School of Medicine, 4001 Rollins Research Building, Atlanta, GA, 30322, USA.,Department of Neurology, Emory School of Medicine, 4001 Rollins Research Building, Atlanta, GA, 30322, USA
| | - Jennifer A Vance
- AIT Bioscience, 7840 Innovation Blvd., Indianapolis, IN, 46278, USA
| | - Benjamin D Reeves
- Department of Chemistry and Biochemistry, Montana State University, Bozeman, MT, 59715, USA
| | - Kelly K Pertile
- Florey Institute of Neuroscience and Mental Health and The University of Melbourne Dementia Research Centre, Parkville, VIC, 3010, Australia
| | - Rebecca L Rumble
- Florey Institute of Neuroscience and Mental Health and The University of Melbourne Dementia Research Centre, Parkville, VIC, 3010, Australia
| | - Chris J Fowler
- Florey Institute of Neuroscience and Mental Health and The University of Melbourne Dementia Research Centre, Parkville, VIC, 3010, Australia
| | - Brett Trounson
- Florey Institute of Neuroscience and Mental Health and The University of Melbourne Dementia Research Centre, Parkville, VIC, 3010, Australia
| | - David Ames
- Florey Institute of Neuroscience and Mental Health and The University of Melbourne Dementia Research Centre, Parkville, VIC, 3010, Australia
| | - Ralph Martins
- Cooperative Research Centre for Mental Health, Carlton South, VIC, Australia.,School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia.,Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
| | - Ashley I Bush
- Florey Institute of Neuroscience and Mental Health and The University of Melbourne Dementia Research Centre, Parkville, VIC, 3010, Australia.,Cooperative Research Centre for Mental Health, Carlton South, VIC, Australia
| | - Colin L Masters
- Florey Institute of Neuroscience and Mental Health and The University of Melbourne Dementia Research Centre, Parkville, VIC, 3010, Australia.,Cooperative Research Centre for Mental Health, Carlton South, VIC, Australia
| | - Paul A Grieco
- Department of Chemistry and Biochemistry, Montana State University, Bozeman, MT, 59715, USA
| | - Edward A Dratz
- Department of Chemistry and Biochemistry, Montana State University, Bozeman, MT, 59715, USA
| | - Blaine R Roberts
- Department of Biochemistry, Emory School of Medicine, 4001 Rollins Research Building, Atlanta, GA, 30322, USA. .,Department of Neurology, Emory School of Medicine, 4001 Rollins Research Building, Atlanta, GA, 30322, USA.
| |
Collapse
|
25
|
Fowler CJ, Stoops E, Rainey‐Smith SR, Vanmechelen E, Vanbrabant J, Dewit N, Mauroo K, Maruff P, Rowe CC, Fripp J, Li Q, Bourgeat P, Collins SJ, Martins RN, Masters CL, Doecke JD. Plasma p‐tau181/Aβ
1‐42
ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ
1‐42
and future cognitive decline. Alz & Dem Diag Ass & Dis Mo 2022; 14:e12375. [DOI: 10.1002/dad2.12375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Accepted: 09/28/2022] [Indexed: 11/26/2022]
Affiliation(s)
| | | | - Stephanie R. Rainey‐Smith
- School of Medical and Health Sciences Centre of Excellence for Alzheimer's Disease Research & Care Edith Cowan University Joondalup Western Australia Australia
| | | | | | | | | | | | - Christopher C. Rowe
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
- Austin Health, Molecular Imaging Research and The Florey Department of Neuroscience University of Melbourne Melbourne Victoria Australia
| | - Jurgen Fripp
- Australian E‐Health Research Centre CSIRO Herston Queensland Australia
| | - Qiao‐Xin Li
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
| | - Pierrick Bourgeat
- Australian E‐Health Research Centre CSIRO Herston Queensland Australia
| | - Steven J. Collins
- Department of Medicine (RMH) The University of Melbourne Melbourne Victoria Australia
| | - Ralph N. Martins
- School of Medical and Health Sciences Centre of Excellence for Alzheimer's Disease Research & Care Edith Cowan University Joondalup Western Australia Australia
- Department of Biological Sciences Macquarie University North Ryde New South Wales Australia
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
| | - James D. Doecke
- Australian E‐Health Research Centre CSIRO Herston Queensland Australia
| |
Collapse
|
26
|
Doré V, Doecke JD, Saad ZS, Triana‐Baltzer G, Slemmon R, Krishnadas N, Bourgeat P, Huang K, Burnham S, Fowler C, Rainey‐Smith SR, Bush AI, Ward L, Robertson J, Martins RN, Masters CL, Villemagne VL, Fripp J, Kolb HC, Rowe CC. Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. Alz & Dem Diag Ass & Dis Mo 2022; 14:e12307. [PMID: 35415202 PMCID: PMC8984092 DOI: 10.1002/dad2.12307] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Accepted: 03/06/2022] [Indexed: 11/11/2022]
Abstract
Introduction We evaluated a new Simoa plasma assay for phosphorylated tau (P‐tau) at aa217 enhanced by additional p‐tau sites (p217+tau). Methods Plasma p217+tau levels were compared to 18F‐NAV4694 amyloid beta (Aβ) positron emission tomography (PET) and 18F‐MK6240 tau PET in 174 cognitively impaired (CI) and 223 cognitively unimpaired (CU) participants. Results Compared to Aβ− CU, the plasma levels of p217+tau increased 2‐fold in Aβ+ CU and 3.5‐fold in Aβ+ CI. In Aβ− the p217+tau levels did not differ significantly between CU and CI. P217+tau correlated with Aβ centiloids P = .67 (CI, P = .64; CU, P = .45) and tau SUVRMTP = .63 (CI, P = .69; CU, P = .34). Area under curve (AUC) for Alzheimer's disease (AD) dementia versus Aβ− CU was 0.94, for AD dementia versus other dementia was 0.93, for Aβ+ versus Aβ− PET was 0.89, and for tau+ versus tau− PET was 0.89. Discussion Plasma p217+tau levels elevate early in the AD continuum and correlate well with Aβ and tau PET.
Collapse
Affiliation(s)
- Vincent Doré
- The Australian e‐Health Research Centre CSIRO Melbourne Victoria Australia
- Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
| | - James D. Doecke
- The Australian e‐Health Research Centre CSIRO Brisbane Queensland Australia
| | - Ziad S. Saad
- Neuroscience Biomarkers Janssen Research and Development La Jolla California USA
| | | | - Randy Slemmon
- Neuroscience Biomarkers Janssen Research and Development La Jolla California USA
| | - Natasha Krishnadas
- Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
| | - Pierrick Bourgeat
- The Australian e‐Health Research Centre CSIRO Brisbane Queensland Australia
| | - Kun Huang
- Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
| | - Samantha Burnham
- The Australian e‐Health Research Centre CSIRO Melbourne Victoria Australia
| | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
| | | | - Ashley I. Bush
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
- Florey Department of Neuroscience and Mental Health The University of Melbourne Melbourne Victoria Australia
| | - Larry Ward
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
| | - Jo Robertson
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
| | - Ralph N. Martins
- Edith Cowan University Joondalup Western Australia Australia
- Centre for Healthy Ageing, Health Futures Institute Murdoch University Murdoch Western Australia Australia
- McCusker Alzheimer's Research Foundation Nedlands Western Australia Australia
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
| | - Victor L. Villemagne
- Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
- Department of Psychiatry University of Pittsburgh Pittsburgh Pennsylvania USA
| | - Jurgen Fripp
- The Australian e‐Health Research Centre CSIRO Brisbane Queensland Australia
| | - Hartmuth C. Kolb
- Neuroscience Biomarkers Janssen Research and Development La Jolla California USA
| | - Christopher C. Rowe
- Department of Molecular Imaging & Therapy Austin Health Melbourne Victoria Australia
- The Florey Institute of Neuroscience and Mental Health Melbourne Victoria Australia
- Florey Department of Neuroscience and Mental Health The University of Melbourne Melbourne Victoria Australia
| |
Collapse
|
27
|
Eqbal A, Martin A, Doecke JD, Patrick D. Low dose thioguanine guided by therapeutic drug monitoring is a safe and effective alternative in inflammatory bowel disease patients intolerant to conventional thiopurines. Intern Med J 2021; 53:559-567. [PMID: 34874611 DOI: 10.1111/imj.15639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 11/18/2021] [Accepted: 11/25/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND AIMS Thioguanine is an alternative thiopurine for IBD patients. We evaluated the short-term efficacy and safety of low dose therapeutic drug monitored (TDM) thioguanine. METHODS A retrospective evaluation of IBD patients intolerant to conventional thiopurines started on thioguanine from 2017-2019 with dosing guided by TDM was conducted. Clinical response was defined for Ulcerative colitis (UC) as a reduction of partial MAYO score ≥ 3 with reduction in rectal bleeding score of at least 1 and a final rectal bleeding sub score of 0-1 at week 12 of therapy. Crohn's disease (CD) response was defined as a reduction of Harvey-Bradshaw index ≥ 3 (HBI) at week 12 of therapy. Remission was defined in UC as partial MAYO score of < 2 and in CD as HBI score of < 5. RESULTS 46 patients were included in the study. The median thioguanine dose was 20 mg/day (SD 7.3, range: 10-40 mg/day) with a median 6-TGN level of 564 pmol/8×108 (IQR 517) for CD and 672 pmol/8×108 (IQR 349) for UC. The overall clinical response rate was 62% (13/21), intention to treat (ITT). Maintenance of remission was 76% (19/25, ITT). 37% (17/46) of patients experienced an adverse effect. No early cases of NRH were seen. CONCLUSION Thioguanine was tolerated well in 63% of patients. Clinical response was seen in 62 % of and maintenance of remission was high at 76 %. No cases of early NRH were seen. Longer-term follow-up is required to ensure safety and to assess durability of response. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- A Eqbal
- Department of Gastroenterology and Hepatology, Sunshine Coast University Public Hospital, Sunshine Coast, Queensland, Australia
| | - A Martin
- Department of Gastroenterology and Hepatology, Sunshine Coast University Public Hospital, Sunshine Coast, Queensland, Australia
| | - J D Doecke
- Department of Gastroenterology and Hepatology, Sunshine Coast University Public Hospital, Sunshine Coast, Queensland, Australia.,CSIRO Health and Biosecurity/Australian E-Health Research Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
| | - D Patrick
- Department of Gastroenterology and Hepatology, Sunshine Coast University Public Hospital, Sunshine Coast, Queensland, Australia
| |
Collapse
|
28
|
Shishegar R, Chai TY, Cox T, Lamb F, Robertson JS, Laws SM, Porter T, Fripp J, Doecke JD, Tosun‐Turgut D, Maruff PT, Savage G, Rowe CC, Masters CL, Weiner MW, Villemagne VL, Burnham SC. Empirically derived composite cognitive test scores to predict preclinical and clinical stages of Alzheimer’s disease. Alzheimers Dement 2021. [DOI: 10.1002/alz.053040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Rosita Shishegar
- The Australian e‐Health Research Centre, CSIRO Melbourne VIC Australia
- School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University Monash VIC Australia
| | - Tze Young Chai
- The Australian e‐Health Research Centre, CSIRO Melbourne VIC Australia
| | - Timothy Cox
- The Australian e‐Health Research Centre, CSIRO Melbourne VIC Australia
| | | | - Joanne S. Robertson
- The Florey Institute of Neuroscience and Mental Health, Melbourne VIC Australia
| | | | - Tenielle Porter
- Cooperative Research Centre for Mental Health Melbourne VIC Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - James D. Doecke
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Duygy Tosun‐Turgut
- Department of Radiology and Biomedical Imaging, University of California‐San Francisco San Francisco CA USA
| | | | | | - Christopher C. Rowe
- Departments of Medicine and Molecular Imaging, University of Melbourne, Austin Health Melbourne VIC Australia
| | - Colin L. Masters
- The Florey Institute of Neuroscience and Mental Health, Melbourne VIC Australia
| | - Mike W. Weiner
- University of California San Francisco San Francisco CA USA
| | - Victor L.L. Villemagne
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
- The University of Pittsburgh Pittsburgh PA USA
| | | |
Collapse
|
29
|
Cox T, Shishegar R, Lim YY, Robertson J, Lamb F, Laws SM, Porter T, Fripp J, Doecke JD, Maruff PT, Savage G, Rowe CC, Masters CL, Villemagne VL, Burnham SC. Unpacking cognitive composites: A longitudinal analysis. Alzheimers Dement 2021. [DOI: 10.1002/alz.053103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Timothy Cox
- The Australian e‐Health Research Centre, CSIRO Melbourne VIC Australia
| | - Rosita Shishegar
- The Australian e‐Health Research Centre, CSIRO Melbourne VIC Australia
- Turner Institute for Brain and Mental Health, School of Psychological Sciences Monash University Melbourne VIC Australia
| | - Yen Ying Lim
- Turner Institute for Brain and Mental Health, Monash University Melbourne VIC Australia
| | - Joanne Robertson
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne Parkville VIC Australia
| | | | - Simon M Laws
- Curtin University Perth WA Australia
- Edith Cowan University Joondalup WA Australia
| | | | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - James D Doecke
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | | | | | - Christopher C Rowe
- Austin Health Melbourne VIC Australia
- The Florey Department of Neuroscience and Mental Health, The University of Melbourne Melbourne VIC Australia
| | - Colin L Masters
- Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
| | | | | | | |
Collapse
|
30
|
Vacher M, Porter T, Milicic L, Dore V, Bourgeat P, Villemagne VL, Doecke JD, Laws SM, Heng JI. Identification of neurodevelopmental gene variants implicated in age‐related brain morphological changes and cortical atrophy. Alzheimers Dement 2021. [DOI: 10.1002/alz.051974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Michael Vacher
- Edith Cowan University Joondalup WA Australia
- Commonwealth Scientific and Industrial Research Organisation Floreat WA Australia
| | | | | | - Vincent Dore
- Department of Molecular Imaging, Austin Health Melbourne VIC Australia
- Austin Health, Melbourne Australia
- The Australian e‐Health Research Centre, CSIRO Melbourne VIC Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Victor L.L. Villemagne
- Departments of Medicine and Molecular Imaging, University of Melbourne, Austin Health Melbourne VIC Australia
- The University of Pittsburgh Pittsburgh PA USA
| | - James D. Doecke
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Simon M. Laws
- Edith Cowan University Joondalup WA Australia
- Curtin University Perth WA Australia
| | | |
Collapse
|
31
|
Rowe CC, Doecke JD, Saad ZS, Triana‐Baltzer G, Slemmon JR, Krishnadas N, Fowler CJ, Rainey‐Smith SR, Ward L, Robertson J, Martins RN, Fripp J, Masters CL, Villemagne VL, Kolb HC, Dore V. Plasma p217+tau concordance with
18
F‐NAV4694 beta‐amyloid and
18
F‐MK6240 tau PET in mild Alzheimer’s disease and cognitively unimpaired participants in the AIBL/ADNeT cohort. Alzheimers Dement 2021. [DOI: 10.1002/alz.055706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Christopher C. Rowe
- The Florey Department of Neuroscience and Mental Health, The University of Melbourne Melbourne VIC Australia
- Australian Dementia Network (ADNeT) Melbourne Australia
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
| | - James D. Doecke
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Ziad S. Saad
- Janssen Research and Development LLC San Diego CA USA
| | | | | | - Natasha Krishnadas
- Florey Department of Neuroscience and Mental Health, University of Melbourne Melbourne VIC Australia
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
| | - Christopher J. Fowler
- Florey Institute of Neuroscience and Mental Health Melbourne Melbourne VIC Australia
| | | | - Larry Ward
- The University of Melbourne Parkville VIC Australia
| | - Joanne Robertson
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne Parkville VIC Australia
| | - Ralph N. Martins
- Co‐operative research Centre (CRC) for Mental Health Carlton South VIC Australia
- Department of Biomedical Sciences, Macquarie University Macquarie Park NSW Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
| | - Colin L. Masters
- Florey Institute of Neuroscience and Mental Health Melbourne VIC Australia
| | | | | | - Vincent Dore
- CSIRO Health and Biosecurity, Australian E‐Health Research Centre Brisbane QLD Australia
- Austin Health Melbourne Australia
| |
Collapse
|
32
|
Klatt S, Doecke JD, Roberts A, Boughton BA, Masters CL, Horne M, Roberts BR. A six-metabolite panel as potential blood-based biomarkers for Parkinson's disease. NPJ Parkinsons Dis 2021; 7:94. [PMID: 34650080 PMCID: PMC8516864 DOI: 10.1038/s41531-021-00239-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 09/13/2021] [Indexed: 12/15/2022] Open
Abstract
Characterisation and diagnosis of idiopathic Parkinson's disease (iPD) is a current challenge that hampers both clinical assessment and clinical trial development with the potential inclusion of non-PD cases. Here, we used a targeted mass spectrometry approach to quantify 38 metabolites extracted from the serum of 231 individuals. This cohort is currently one of the largest metabolomic studies including iPD patients, drug-naïve iPD, healthy controls and patients with Alzheimer's disease as a disease-specific control group. We identified six metabolites (3-hydroxykynurenine, aspartate, beta-alanine, homoserine, ornithine (Orn) and tyrosine) that are significantly altered between iPD patients and control participants. A multivariate model to predict iPD from controls had an area under the curve (AUC) of 0.905, with an accuracy of 86.2%. This panel of metabolites may serve as a potential prognostic or diagnostic assay for clinical trial prescreening, or for aiding in diagnosing pathological disease in the clinic.
Collapse
Affiliation(s)
- Stephan Klatt
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, 3052, Australia
- Cooperative Research Centre for Mental Health, Parkville, VIC, 3052, Australia
| | - James D Doecke
- Cooperative Research Centre for Mental Health, Parkville, VIC, 3052, Australia
- Australian e-Health Research Centre, CSIRO, Brisbane, QLD, Australia
| | - Anne Roberts
- Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, 30322, USA
| | - Berin A Boughton
- School of Biosciences, The University of Melbourne, Parkville, VIC, 3052, Australia
- Australian National Phenome Centre, Murdoch University, Murdoch, WA, 6150, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, 3052, Australia
- Cooperative Research Centre for Mental Health, Parkville, VIC, 3052, Australia
| | - Malcolm Horne
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, 3052, Australia
| | - Blaine R Roberts
- Department of Biochemistry, Emory University School of Medicine, Atlanta, GA, 30322, USA.
- Department of Neurology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
| |
Collapse
|
33
|
Gardener SL, Weinborn M, Sohrabi HR, Doecke JD, Bourgeat P, Rainey-Smith SR, Shen KK, Fripp J, Taddei K, Maruff P, Salvado O, Savage G, Ames D, Masters CL, Rowe CC, Martins RN. Longitudinal Trajectories in Cortical Thickness and Volume Atrophy: Superior Cognitive Performance Does Not Protect Against Brain Atrophy in Older Adults. J Alzheimers Dis 2021; 81:1039-1052. [PMID: 33935071 PMCID: PMC8293653 DOI: 10.3233/jad-201243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background: Previous research has identified a small subgroup of older adults that maintain a high level of cognitive functioning well into advanced age. Investigation of those with superior cognitive performance (SCP) for their age is important, as age-related decline has previously been thought to be inevitable. Objective: Preservation of cortical thickness and volume was evaluated in 76 older adults with SCP and 100 typical older adults (TOAs) assessed up to five times over six years. Methods: Regions of interest (ROIs) found to have been associated with super-aging status (a construct similar to SCP status) in previous literature were investigated, followed by a discovery phase analyses of additional regions. SCPs were aged 70 + at baseline, scoring at/above normative memory (CVLT-II) levels for demographically similar individuals aged 30–44 years old, and in the unimpaired range for all other cognitive domains over the course of the study. Results: In linear mixed models, following adjustment for multiple comparisons, there were no significant differences between rates of thinning or volume atrophy between SCPs and TOAs in previously identified ROIs, or the discovery phase analyses. With only amyloid-β negative individuals in the analyses, again there were no significant differences between SCPs and TOAs. Conclusion: The increased methodological rigor in classifying groups, together with the influence of cognitive reserve, are discussed as potential factors accounting for our findings as compared to the extant literature on those with superior cognitive performance for their age.
Collapse
Affiliation(s)
- Samantha L Gardener
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia
| | - Michael Weinborn
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia.,School of Psychological Science, University of Western Australia, Crawley, Western Australia, Australia
| | - Hamid R Sohrabi
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia.,College of Science, Health, Engineering and Education, Murdoch University, Murdoch, Western Australia, Australia.,Department of Biomedical Sciences, Macquarie University, New South Wales, Australia
| | - James D Doecke
- CSIRO Health and Biosecurity/Australian eHealth Research Centre, Herston, Queensland, Australia
| | - Pierrick Bourgeat
- CSIRO Health and Biosecurity/Australian eHealth Research Centre, Herston, Queensland, Australia
| | - Stephanie R Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia.,School of Psychological Science, University of Western Australia, Crawley, Western Australia, Australia.,Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia
| | - Kai-Kai Shen
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia.,CSIRO Health and Biosecurity/Australian eHealth Research Centre, Herston, Queensland, Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity/Australian eHealth Research Centre, Herston, Queensland, Australia
| | - Kevin Taddei
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia
| | - Paul Maruff
- CogState, Ltd., Melbourne, Victoria, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity/Australian eHealth Research Centre, Herston, Queensland, Australia.,CSIRO Data61, Sydney, Australia
| | - Greg Savage
- ARC Centre of Excellence in Cognition and its Disorders and Department of Psychology, Macquarie University, New South Wales, Australia
| | - David Ames
- National Ageing Research Institute, Royal Melbourne Hospital, Melbourne, Australia.,Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia.,Florey Department of the University of Melbourne
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia.,Australian Alzheimer's Research Foundation, Perth, Western Australia, Australia.,Department of Biomedical Sciences, Macquarie University, New South Wales, Australia
| | | |
Collapse
|
34
|
Doecke JD, Francois C, Fowler CJ, Stoops E, Bourgeat P, Rainey-Smith SR, Li QX, Masters CL, Martins RN, Villemagne VL, Collins SJ, Vanderstichele HM. Core Alzheimer's disease cerebrospinal fluid biomarker assays are not affected by aspiration or gravity drip extraction methods. Alzheimers Res Ther 2021; 13:79. [PMID: 33863377 PMCID: PMC8052760 DOI: 10.1186/s13195-021-00812-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 03/22/2021] [Indexed: 11/10/2022]
Abstract
BACKGROUND CSF biomarkers are well-established for routine clinical use, yet a paucity of comparative assessment exists regarding CSF extraction methods during lumbar puncture. Here, we compare in detail biomarker profiles in CSF extracted using either gravity drip or aspiration. METHODS Biomarkers for β-amyloidopathy (Aβ1-42, Aβ1-40), tauopathy (total tau), or synapse pathology (BACE1, Neurogranin Trunc-p75, α-synuclein) were assessed between gravity or aspiration extraction methods in a sub-population of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study (cognitively normal, N = 36; mild cognitive impairment, N = 8; Alzheimer's disease, N = 6). RESULTS High biomarker concordance between extraction methods was seen (concordance correlation > 0.85). Passing Bablock regression defined low beta coefficients indicating high scalability. CONCLUSIONS Levels of these commonly assessed CSF biomarkers are not influenced by extraction method. Results of this study should be incorporated into new consensus guidelines for CSF collection, storage, and analysis of biomarkers.
Collapse
Affiliation(s)
- James D Doecke
- The Australian e-Health Research Centre, CSIRO, Brisbane, QLD, Australia
| | | | | | | | - Pierrick Bourgeat
- The Australian e-Health Research Centre, CSIRO, Brisbane, QLD, Australia
| | - Stephanie R Rainey-Smith
- Australian Alzheimer's Research Foundation, Perth, WA, Australia.,Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia
| | - Qiao-Xin Li
- University of Melbourne, Melbourne, VIC, Australia
| | | | | | - Victor L Villemagne
- Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, VIC, Australia.,Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
| | | | | |
Collapse
|
35
|
Liu YH, Wang J, Li QX, Fowler CJ, Zeng F, Deng J, Xu ZQ, Zhou HD, Doecke JD, Villemagne VL, Lim YY, Masters CL, Wang YJ. Association of naturally occurring antibodies to β-amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease. Sci Adv 2021; 7:7/1/eabb0457. [PMID: 33523832 PMCID: PMC7775771 DOI: 10.1126/sciadv.abb0457] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Accepted: 11/05/2020] [Indexed: 05/03/2023]
Abstract
The pathological relevance of naturally occurring antibodies to β-amyloid (NAbs-Aβ) in Alzheimer's disease (AD) remains unclear. We aimed to investigate their levels and associations with Aβ burden and cognitive decline in AD in a cross-sectional cohort from China and a longitudinal cohort from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. NAbs-Aβ levels in plasma and cerebrospinal fluid (CSF) were tested according to their epitopes. Levels of NAbs targeting the amino terminus of Aβ increased, and those targeting the mid-domain of Aβ decreased in both CSF and plasma in AD patients. Higher plasma levels of NAbs targeting the amino terminus of Aβ and lower plasma levels of NAbs targeting the mid-domain of Aβ were associated with higher brain amyloidosis at baseline and faster cognitive decline during follow-up. Our findings suggest a dynamic response of the adaptive immune system in the progression of AD and are relevant to current passive immunotherapeutic strategies.
Collapse
Affiliation(s)
- Yu-Hui Liu
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Jun Wang
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Qiao-Xin Li
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - Christopher J Fowler
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - Fan Zeng
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Juan Deng
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Zhi-Qiang Xu
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - Hua-Dong Zhou
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
| | - James D Doecke
- The Australian E-Health Research Centre, CSIRO, Herston, Queensland, Australia
| | - Victor L Villemagne
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
| | - Yen Ying Lim
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - Colin L Masters
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.
| | - Yan-Jiang Wang
- Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Third Military Medical University, Chongqing, China.
- Chongqing Key Laboratory of Ageing and Brain Diseases, Chongqing, China
- Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai 200031, China
| |
Collapse
|
36
|
Doecke JD, Francois C, Fowler CJ, Stoops E, Rainey‐Smith SR, Li Q, Masters CL, Martins RN, Villemagne VLL, Vanderstichele HM. Cerebrospinal fluid biomarker levels are not affected by aspiration or gravity drip extraction methods in Alzheimer’s disease: The AIBL study. Alzheimers Dement 2020. [DOI: 10.1002/alz.046703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
| | | | | | | | | | | | | | | | - Victor LL Villemagne
- Department of Nuclear Medicine and Centre for PET Austin Health Heidelberg Australia
| | | |
Collapse
|
37
|
Vacher M, Porter T, Milicic L, Peretti M, Dore V, Villemagne VLL, Laws SM, Doecke JD. Identification of genetic markers linked to accelerated brain volume changes in Aβ‐positive population. Alzheimers Dement 2020. [DOI: 10.1002/alz.041386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Michael Vacher
- Commonwealth Scientific and Industrial Research Organisation Perth Australia
| | | | | | - Madeline Peretti
- Cooperative Research Centre for Mental Health Melbourne Australia
| | - Vincent Dore
- The Australian e‐Health Research Centre, CSIRO Melbourne Australia
| | | | | | | |
Collapse
|
38
|
van Havre Z, Maruff P, Villemagne VL, Mengersen K, Rousseau J, White N, Doecke JD. Identification of Pre-Clinical Alzheimer's Disease in a Population of Elderly Cognitively Normal Participants. J Alzheimers Dis 2020; 73:683-693. [PMID: 31868673 DOI: 10.3233/jad-191095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Alzheimer's disease (AD) has a long pathological process, with an approximate lead-time of 20 years. During the early stages of the disease process, little evidence of the building pathology is identifiable without cerebrospinal fluid and/or imaging analyses. Clinical manifestations of AD do not present until irreversible pathological changes have occurred. Given an opportunity to provide treatment prior to irreversible pathological change, this study aims to identify a subgroup of cognitively normal (CN) participants from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), where subtle changes in cognition are indicative of early AD-related pathology. Using a Bayesian method for unsupervised clustering via mixture models, we define an aggregate measure of posterior probabilities (AMPP score) establishing the likelihood of pre-clinical AD. From Baseline through to 54 months, visuo-spatial function had the greatest contribution to the AMPP score, followed by attention and processing speed and visual memory. Participants with the highest AMPP scores had both increasing neo-cortical amyloid burden and decreasing hippocampus volume over 54 months, compared to those in the lowest category with stable amyloid burden and hippocampus volume. The identification of a possible pre-clinical stage in CN participants via this method, without the aid of disease specific biomarkers, represents an important step in utilizing the strength of cognitive composite scores for the early detection of AD pathology.
Collapse
Affiliation(s)
- Zoe van Havre
- ACEMS, Queensland University of Technology, Queensland, Australia.,CEREMADE, Universite Paris Dauphine, Paris, France
| | - Paul Maruff
- Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia.,CogState Ltd., Victoria, Australia
| | - Victor L Villemagne
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.,Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Kerrie Mengersen
- ACEMS, Queensland University of Technology, Queensland, Australia
| | | | - Nicole White
- ACEMS, Queensland University of Technology, Queensland, Australia
| | - James D Doecke
- CSIRO Health and Biosecurity/Australian e-Health Research Centre, Herston, Queensland, Australia
| |
Collapse
|
39
|
Cespedes MI, McGree JM, Drovandi CC, Mengersen K, Fripp J, Doecke JD. Relative rate of change in cognitive score network dynamics via Bayesian hierarchical models reveal spatial patterns of neurodegeneration. Stat Med 2020; 39:2695-2713. [PMID: 32419227 DOI: 10.1002/sim.8568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Revised: 04/15/2020] [Accepted: 04/16/2020] [Indexed: 11/11/2022]
Abstract
The degeneration of the human brain is a complex process, which often affects certain brain regions due to healthy aging or disease. This degeneration can be evaluated on regions of interest (ROI) in the brain through probabilistic networks and morphological estimates. Current approaches for finding such networks are limited to analyses at discrete neuropsychological stages, which cannot appropriately account for connectivity dynamics over the onset of cognitive deterioration, and morphological changes are seldom unified with connectivity networks, despite known dependencies. To overcome these limitations, a probabilistic wombling model is proposed to simultaneously estimate ROI cortical thickness and covariance networks contingent on rates of change in cognitive decline. This proposed model was applied to analyze longitudinal data from healthy control (HC) and Alzheimer's disease (AD) groups and found connection differences pertaining to regions, which play a crucial role in lasting cognitive impairment, such as the entorhinal area and temporal regions. Moreover, HC cortical thickness estimates were significantly higher than those in the AD group across all ROIs. The analyses presented in this work will help practitioners jointly analyze brain tissue atrophy at the ROI-level conditional on neuropsychological networks, which could potentially allow for more targeted therapeutic interventions.
Collapse
Affiliation(s)
- Marcela I Cespedes
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Herston, Queensland, Australia
| | - James M McGree
- ARC Centre for Mathematical and Statistical Frontiers and School of Mathematical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Christopher C Drovandi
- ARC Centre for Mathematical and Statistical Frontiers and School of Mathematical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Kerrie Mengersen
- ARC Centre for Mathematical and Statistical Frontiers and School of Mathematical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Herston, Queensland, Australia
| | - James D Doecke
- CSIRO Health and Biosecurity, Australian E-Health Research Centre, Herston, Queensland, Australia
| |
Collapse
|
40
|
Burnham SC, Fandos N, Fowler C, Pérez-Grijalba V, Dore V, Doecke JD, Shishegar R, Cox T, Fripp J, Rowe C, Sarasa M, Masters CL, Pesini P, Villemagne VL. Longitudinal evaluation of the natural history of amyloid-β in plasma and brain. Brain Commun 2020; 2:fcaa041. [PMID: 32954297 PMCID: PMC7425352 DOI: 10.1093/braincomms/fcaa041] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Revised: 02/26/2020] [Accepted: 03/04/2020] [Indexed: 01/03/2023] Open
Abstract
Plasma amyloid-β peptide concentration has recently been shown to have high accuracy to predict amyloid-β plaque burden in the brain. These amyloid-β plasma markers will allow wider screening of the population and simplify and reduce screening costs for therapeutic trials in Alzheimer’s disease. The aim of this study was to determine how longitudinal changes in blood amyloid-β track with changes in brain amyloid-β. Australian Imaging, Biomarker and Lifestyle study participants with a minimum of two assessments were evaluated (111 cognitively normal, 7 mild cognitively impaired, 15 participants with Alzheimer’s disease). Amyloid-β burden in the brain was evaluated through PET and was expressed in Centiloids. Total protein amyloid-β 42/40 plasma ratios were determined using ABtest® assays. We applied our method for obtaining natural history trajectories from short term data to measures of total protein amyloid-β 42/40 plasma ratios and PET amyloid-β. The natural history trajectory of total protein amyloid-β 42/40 plasma ratios appears to approximately mirror that of PET amyloid-β, with both spanning decades. Rates of change of 7.9% and 8.8%, were observed for total protein amyloid-β 42/40 plasma ratios and PET amyloid-β, respectively. The trajectory of plasma amyloid-β preceded that of brain amyloid-β by a median value of 6 years (significant at 88% confidence interval). These findings, showing the tight association between changes in plasma and brain amyloid-β, support the use of plasma total protein amyloid-β 42/40 plasma ratios as a surrogate marker of brain amyloid-β. Also, that plasma total protein amyloid-β 42/40 plasma ratios has potential utility in monitoring trial participants, and as an outcome measure.
Collapse
Affiliation(s)
- Samantha C Burnham
- The Australian e-Health Research Centre, CSIRO Health & Biosecurity, Parkville, VIC 3052, Australia.,Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA 6027, Australia
| | | | - Christopher Fowler
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3010, Australia
| | | | - Vincent Dore
- The Australian e-Health Research Centre, CSIRO Health & Biosecurity, Parkville, VIC 3052, Australia.,Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC 3084, Australia
| | - James D Doecke
- The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Herston 4029, Australia
| | - Rosita Shishegar
- The Australian e-Health Research Centre, CSIRO Health & Biosecurity, Parkville, VIC 3052, Australia
| | - Timothy Cox
- The Australian e-Health Research Centre, CSIRO Health & Biosecurity, Parkville, VIC 3052, Australia
| | - Jurgen Fripp
- The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Herston 4029, Australia
| | - Christopher Rowe
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3010, Australia.,Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC 3084, Australia.,Department of Medicine, The University of Melbourne, Parkville, VIC 3052, Australia
| | | | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3010, Australia
| | | | - Victor L Villemagne
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC 3084, Australia.,Department of Medicine, The University of Melbourne, Parkville, VIC 3052, Australia
| |
Collapse
|
41
|
Doecke JD, Ward L, Burnham SC, Villemagne VL, Li QX, Collins S, Fowler CJ, Manuilova E, Widmann M, Rainey-Smith SR, Martins RN, Masters CL. Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimers Res Ther 2020; 12:36. [PMID: 32234072 PMCID: PMC7110644 DOI: 10.1186/s13195-020-00595-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Accepted: 03/09/2020] [Indexed: 12/17/2022]
Abstract
Background β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid method to define AD pathology. Methods Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1–42) (Aβ42), Aβ (1–40) (Aβ40), total tau (tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological AD via PET imaging. Results Ratios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 had higher receiver operator characteristic—area under the curve (all 0.94), and greater concordance with Aβ-PET (overall percentage agreement ~ 90%), compared with individual biomarkers. Conclusion Strong concordance between CSF biomarkers and Aβ-PET status was observed overall, including for cognitively normal participants, further strengthening the association between these markers of AD neuropathological burden for both developmental research studies and for use in clinical trials. Supplementary information The online version of this article (10.1186/s13195-020-00595-5).
Collapse
Affiliation(s)
- James D Doecke
- Cooperative Research Council for Mental Health, Melbourne, Victoria, 3052, Australia. .,Australian E-Health Research Centre, CSIRO Health & Biosecurity, Level 5, 901/16 Royal Brisbane & Women's Hospital, Brisbane, Queensland, 4029, Australia.
| | - Larry Ward
- Cooperative Research Council for Mental Health, Melbourne, Victoria, 3052, Australia
| | - Samantha C Burnham
- Australian E-Health Research Centre, CSIRO, Parkville, Melbourne, Victoria, 3052, Australia
| | - Victor L Villemagne
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Melbourne, Victoria, 3010, Australia.,Department of Molecular Imaging and Therapy, Center for PET, Austin Health, Heidelberg, Victoria, 3084, Australia
| | - Qiao-Xin Li
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Melbourne, Victoria, 3010, Australia
| | - Steven Collins
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Melbourne, Victoria, 3010, Australia.,Department of Medicine (RMH), The University of Melbourne, Parkville, Melbourne, Victoria, 3052, Australia
| | - Christopher J Fowler
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Melbourne, Victoria, 3010, Australia
| | | | - Monika Widmann
- Roche Diagnostics GmbH, Sandhoferstrasse 116, 68305, Mannheim, Germany
| | - Stephanie R Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, 6027, Australia
| | - Ralph N Martins
- Department of Biomedical Sciences, Macquarie University, North Ryde, New South Wales, 2113, Australia.,School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Western Australia, 6009, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Melbourne, Victoria, 3010, Australia
| | | |
Collapse
|
42
|
Doecke JD, Pérez-Grijalba V, Fandos N, Fowler C, Villemagne VL, Masters CL, Pesini P, Sarasa M. Total Aβ 42/Aβ 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology 2020; 94:e1580-e1591. [PMID: 32179698 PMCID: PMC7251518 DOI: 10.1212/wnl.0000000000009240] [Citation(s) in RCA: 87] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Accepted: 10/24/2019] [Indexed: 12/30/2022] Open
Abstract
OBJECTIVE To explore whether the plasma total β-amyloid (Aβ) Aβ42/Aβ40 ratio is a reliable predictor of the amyloid-PET status by exploring the association between these 2 variables in a subset of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging cohort. METHODS Taking plasma samples at 3 separate time points, month 18 (n = 176), month 36 (n = 169), and month 54 (n = 135), we assessed the total Aβ42/Aβ40 ratio in plasma (TP42/40) with regard to neocortical Aβ burden via PET standardized uptake value ratio (SUVR) and investigated both association with Aβ-PET status and correlation (and agreement) with SUVR. RESULTS The TP42/40 plasma ratio was significantly reduced in amyloid-PET-positive participants at all time points (p < 0.0001). Adjusting for covariates age, gender, APOE ε4 allele status, and clinical classification clearly affects the significance, with p values reduced and only comparisons at 54 months retaining significance (p = 0.006). Correlations with SUVR were similar across each time point, with Spearman ρ reaching -0.64 (p < 0.0001). Area under the curve values were highly reproducible over time points, with values ranging from 0.880 at 36 months to 0.913 at 54 months. In assessments of the healthy control group only, the same relationships were found. CONCLUSIONS The current study demonstrates reproducibility of the plasma assay to discriminate between amyloid-PET positive and negative over 3 time points, which can help to substantially reducing the screening rate of failure for clinical trials targeting preclinical or prodromal disease. CLASSIFICATION OF EVIDENCE This study provides Class II evidence that plasma total Aβ42/Aβ40 ratio is associated with neocortical amyloid burden as measured by PET SUVR.
Collapse
Affiliation(s)
- James D Doecke
- From the CSIRO Health and Biosecurity/Australian E-Health Research Centre (J.D.D.), Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; R&D Department (V.P.-G., N.F., P.P., M.S.), Araclon Biotech Ltd, Zaragoza, Spain; and The Florey Institute of Neuroscience and Mental Health (C.F., V.L.V., C.L.M.), University of Melbourne, Parkville, Victoria, Australia
| | - Virginia Pérez-Grijalba
- From the CSIRO Health and Biosecurity/Australian E-Health Research Centre (J.D.D.), Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; R&D Department (V.P.-G., N.F., P.P., M.S.), Araclon Biotech Ltd, Zaragoza, Spain; and The Florey Institute of Neuroscience and Mental Health (C.F., V.L.V., C.L.M.), University of Melbourne, Parkville, Victoria, Australia
| | - Noelia Fandos
- From the CSIRO Health and Biosecurity/Australian E-Health Research Centre (J.D.D.), Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; R&D Department (V.P.-G., N.F., P.P., M.S.), Araclon Biotech Ltd, Zaragoza, Spain; and The Florey Institute of Neuroscience and Mental Health (C.F., V.L.V., C.L.M.), University of Melbourne, Parkville, Victoria, Australia
| | - Christopher Fowler
- From the CSIRO Health and Biosecurity/Australian E-Health Research Centre (J.D.D.), Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; R&D Department (V.P.-G., N.F., P.P., M.S.), Araclon Biotech Ltd, Zaragoza, Spain; and The Florey Institute of Neuroscience and Mental Health (C.F., V.L.V., C.L.M.), University of Melbourne, Parkville, Victoria, Australia
| | - Victor L Villemagne
- From the CSIRO Health and Biosecurity/Australian E-Health Research Centre (J.D.D.), Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; R&D Department (V.P.-G., N.F., P.P., M.S.), Araclon Biotech Ltd, Zaragoza, Spain; and The Florey Institute of Neuroscience and Mental Health (C.F., V.L.V., C.L.M.), University of Melbourne, Parkville, Victoria, Australia
| | - Colin L Masters
- From the CSIRO Health and Biosecurity/Australian E-Health Research Centre (J.D.D.), Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; R&D Department (V.P.-G., N.F., P.P., M.S.), Araclon Biotech Ltd, Zaragoza, Spain; and The Florey Institute of Neuroscience and Mental Health (C.F., V.L.V., C.L.M.), University of Melbourne, Parkville, Victoria, Australia
| | - Pedro Pesini
- From the CSIRO Health and Biosecurity/Australian E-Health Research Centre (J.D.D.), Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; R&D Department (V.P.-G., N.F., P.P., M.S.), Araclon Biotech Ltd, Zaragoza, Spain; and The Florey Institute of Neuroscience and Mental Health (C.F., V.L.V., C.L.M.), University of Melbourne, Parkville, Victoria, Australia.
| | - Manuel Sarasa
- From the CSIRO Health and Biosecurity/Australian E-Health Research Centre (J.D.D.), Royal Brisbane and Women's Hospital, Herston, Queensland, Australia; R&D Department (V.P.-G., N.F., P.P., M.S.), Araclon Biotech Ltd, Zaragoza, Spain; and The Florey Institute of Neuroscience and Mental Health (C.F., V.L.V., C.L.M.), University of Melbourne, Parkville, Victoria, Australia
| | | |
Collapse
|
43
|
Peterson CB, Osborne N, Stingo FC, Bourgeat P, Doecke JD, Vannucci M. Bayesian modeling of multiple structural connectivity networks during the progression of Alzheimer's disease. Biometrics 2020; 76:1120-1132. [PMID: 32026459 DOI: 10.1111/biom.13235] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Revised: 01/10/2020] [Accepted: 01/14/2020] [Indexed: 11/29/2022]
Abstract
Alzheimer's disease is the most common neurodegenerative disease. The aim of this study is to infer structural changes in brain connectivity resulting from disease progression using cortical thickness measurements from a cohort of participants who were either healthy control, or with mild cognitive impairment, or Alzheimer's disease patients. For this purpose, we develop a novel approach for inference of multiple networks with related edge values across groups. Specifically, we infer a Gaussian graphical model for each group within a joint framework, where we rely on Bayesian hierarchical priors to link the precision matrix entries across groups. Our proposal differs from existing approaches in that it flexibly learns which groups have the most similar edge values, and accounts for the strength of connection (rather than only edge presence or absence) when sharing information across groups. Our results identify key alterations in structural connectivity that may reflect disruptions to the healthy brain, such as decreased connectivity within the occipital lobe with increasing disease severity. We also illustrate the proposed method through simulations, where we demonstrate its performance in structure learning and precision matrix estimation with respect to alternative approaches.
Collapse
Affiliation(s)
| | - Nathan Osborne
- Department of Statistics, Rice University, Houston, Texas
| | - Francesco C Stingo
- Department of Statistics, Computer Science, Applications "G. Parenti", University of Florence, Florence, Italy
| | - Pierrick Bourgeat
- Australian eHealth Research Centre, CSIRO Health and Biosecurity, Herston, Queensland, Australia
| | - James D Doecke
- Australian eHealth Research Centre, CSIRO Health and Biosecurity, Herston, Queensland, Australia
| | | |
Collapse
|
44
|
Shen EX, Lord A, Doecke JD, Hanigan K, Irwin J, Cheng RKY, Radford-Smith G. A validated risk stratification tool for detecting high-risk small bowel Crohn's disease. Aliment Pharmacol Ther 2020; 51:281-290. [PMID: 31769537 DOI: 10.1111/apt.15550] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2019] [Revised: 02/16/2019] [Accepted: 09/30/2019] [Indexed: 12/12/2022]
Abstract
BACKGROUND Delays in Crohn's disease (CD) diagnosis are positively associated with ileal location and an increased risk of complications. AIM To develop a simple risk assessment tool to enable primary care physicians to recognise potential ileal CD earlier, shortening the delay to specialist investigation METHODS: Three cohorts were acquired for this study. Cohort 1 included 61 patients retrospectively identified with ileal CD between 2000 and 2010 and 78 matched controls drawn from a cohort referred for investigation of abdominal symptoms. Cohort 2 included 42 individuals diagnosed with ileal CD and 57 controls identified prospectively. Cohort 3 included an additional 84 individuals with ileal CD and 495 without CD referred for colonoscopy. Clinical symptoms and serological biomarkers were acquired and used to develop a risk prediction algorithm. The algorithm was trained independently on each of the three cohorts and tested on the latter two cohorts. RESULTS Altered bowel habit with abdominal pain combined with derangements in white cell count (WCC), albumin and platelet counts were important features in predicting ileal CD (AUC = 0.92, 95% CI = 0.89-0.92). This was validated in cohorts 2 (AUC = 0.96, 95% CI = 0.95-0.98) and 3 (AUC = 0.94, 95% CI = 0.92-0.96). C-reactive protein was independently associated with ileal CD but non-signficant in a multivariate model. CONCLUSION A web-based risk stratification tool for ileal CD has been developed from objective and symptom-based criteria. This tool enables primary care physicians to more confidently request urgent specialist assessment for patients identified as at high risk for ileal CD.
Collapse
Affiliation(s)
- Eddie X Shen
- QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia.,Faculty of Medicine, University of Queensland, Brisbane, Qld, Australia
| | - Anton Lord
- QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia
| | - James D Doecke
- CSIRO Health and Biosecurity/Australian e-Health Research Centre, Brisbane, Qld, Australia
| | | | - James Irwin
- QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia.,Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia
| | - Richard K Y Cheng
- QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia.,Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia
| | - Graham Radford-Smith
- QIMR Berghofer Medical Research Institute, Brisbane, Qld, Australia.,Faculty of Medicine, University of Queensland, Brisbane, Qld, Australia.,Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Qld, Australia
| |
Collapse
|
45
|
Patrick D, Doecke JD, Irwin J, Hanigan K, Simms LA, Howlett M, Radford-Smith GL. Short-term colectomy is avoided in over half of regional patients failing medical therapy for acute severe ulcerative colitis with co-ordinated transfer and tertiary care. Intern Med J 2019; 50:823-829. [PMID: 31589361 DOI: 10.1111/imj.14649] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2019] [Revised: 07/04/2019] [Accepted: 09/23/2019] [Indexed: 12/21/2022]
Abstract
BACKGROUND AND AIMS Many patients presenting with an acute severe ulcerative colitis to a regional hospital are transferred to a metropolitan hospital for specialised care. This study aimed to evaluate the outcomes and characteristics of these patients. METHOD A retrospective observational cohort study was conducted to examine the 30-day colectomy rate using prospectively collected data on 69 consecutive index cases of acute severe ulcerative colitis transferred from regional hospitals to our metropolitan hospital meeting Truelove and Witts criteria. Those that avoided colectomy were followed out to 1 year to examine outcomes. RESULTS The 30-day colectomy rate was 46.4% (32/69) in regional transfer patients. Rescue therapy was administered to 65% (45/69) of patients after transfer to our metropolitan hospital. Colectomy was avoided in 55% of these patients at 30 days. Colectomy free status was maintained in 78% (29/39) of these patients. Mortality was 0% at 30 days and 1 year. CONCLUSION Over 50% of the patients failing therapy in a regional centre and requiring transfer avoided short term colectomy with co-ordinated referral for rescue therapy in a tertiary metropolitan inflammatory bowel disease unit. These patients would have ultimately required colectomy in their regional hospital without intervention.
Collapse
Affiliation(s)
- Desmond Patrick
- Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.,Gut Health Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.,Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia
| | - James D Doecke
- CSIRO Health and Biosecurity/Australian E-Health Research Centre, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
| | - James Irwin
- Gut Health Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Katherine Hanigan
- Gut Health Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Lisa A Simms
- Gut Health Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Mariko Howlett
- Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
| | - Graham L Radford-Smith
- Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.,Gut Health Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.,Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia
| |
Collapse
|
46
|
Dang C, Yassi N, Harrington KD, Xia Y, Lim YY, Ames D, Laws SM, Hickey M, Rainey-Smith S, Sohrabi HR, Doecke JD, Fripp J, Salvado O, Snyder PJ, Weinborn M, Villemagne VL, Rowe CC, Masters CL, Maruff P. Rates of age- and amyloid β-associated cortical atrophy in older adults with superior memory performance. Alzheimers Dement (Amst) 2019; 11:566-575. [PMID: 31909172 PMCID: PMC6939054 DOI: 10.1016/j.dadm.2019.05.005] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Introduction Superior cognitive performance in older adults may reflect underlying resistance to age-associated neurodegeneration. While elevated amyloid β (Aβ) deposition (Aβ+) has been associated with increased cortical atrophy, it remains unknown whether “SuperAgers” may be protected from Aβ-associated neurodegeneration. Methods Neuropsychologically defined SuperAgers (n = 172) and cognitively normal for age (n = 172) older adults from the Australian Imaging, Biomarkers and Lifestyle study were case matched. Rates of cortical atrophy over 8 years were examined by SuperAger classification and Aβ status. Results Of the case-matched SuperAgers and cognitively normal for age older adults, 40.7% and 40.1%, respectively, were Aβ+. Rates of age- and Aβ-associated atrophy did not differ between the groups on any measure. Aβ− individuals displayed the slowest rates of atrophy. Discussion Maintenance of superior memory in late life does not reflect resistance to age- or Aβ-associated atrophy. However, those individuals who reached old age without cognitive impairment nor elevated Aβ deposition (i.e. Aβ−) displayed reduced rates of cortical atrophy.
Collapse
Affiliation(s)
- Christa Dang
- Department of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia.,The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Nawaf Yassi
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.,Department of Medicine and Neurology, Royal Melbourne Hospital, Melbourne, Victoria, Australia
| | - Karra D Harrington
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.,Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia
| | - Ying Xia
- CSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - Yen Ying Lim
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - David Ames
- Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia.,National Ageing Research Institute, Parkville, Victoria, Australia
| | - Simon M Laws
- Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia.,Collaborative Genomics Group, Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia
| | - Martha Hickey
- Department of Obstetrics and Gynaecology, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia
| | - Stephanie Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,Australian Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia
| | - Hamid R Sohrabi
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,School of Psychiatry and Clinical Neurosciences, University of Western Australia, Nedlands, Western Australia, Australia
| | - James D Doecke
- CSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - Jurgen Fripp
- CSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity, the Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - Peter J Snyder
- George & Anne Ryan Institute for Neuroscience, The University of Rhode Island, Kingston, RI, USA
| | - Michael Weinborn
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,Australian Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia.,School of Psychological Science, University of Western Australia, Crawley, Western Australia, Australia
| | - Victor L Villemagne
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.,Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Paul Maruff
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.,CogState Ltd., Melbourne, Victoria, Australia
| | | |
Collapse
|
47
|
Brown BM, Frost N, Rainey-Smith SR, Doecke JD, Weinborn M, Sohrabi HR, Laws SM, Martins RN, Peiffer JJ. O4-06-03: EXPLORING INDIVIDUAL VARIABILITY IN EXERCISE-INDUCED COGNITIVE CHANGE: THE ROLE OF CARDIORESPIRATORY FITNESS AND APOLIPOPROTEIN ε4 ALLELE CARRIAGE. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.4772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
| | | | | | - James D. Doecke
- CSIRO Computational Informatics/Australian e-Health Research Centre; Brisbane Australia
| | | | - Hamid R. Sohrabi
- Edith Cowan University; Joondalup Australia
- Macquarie University; North Ryde Australia
| | | | - Ralph N. Martins
- Edith Cowan University; Joondalup Australia
- Macquarie University; North Ryde Australia
| | | |
Collapse
|
48
|
Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, Rutz S, Widmann M, Leinenbach A, Blennow K. Method comparison study of the Elecsys® β-Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. Clin Biochem 2019; 72:7-14. [PMID: 31129181 DOI: 10.1016/j.clinbiochem.2019.05.006] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Accepted: 05/19/2019] [Indexed: 01/09/2023]
Abstract
BACKGROUND Alzheimer's disease (AD) biomarkers, such as cerebrospinal fluid (CSF) amyloid-β (1-42; Aβ42), can provide high diagnostic accuracy. Several immunoassays are available for Aβ42 quantitation, but standardisation across assays remains an issue. We compared the Elecsys® β-Amyloid (1-42) CSF assay with three assays and two liquid chromatography tandem mass spectrometry (LC-MS/MS) methods. METHODS Three method comparison studies evaluated the correlation between the Elecsys® β-Amyloid (1-42) CSF assay versus: INNOTEST® β-AMYLOID(1-42) (860 samples) and the Roche Diagnostics-developed LC-MS/MS method (250 samples); INNO-BIA AlzBio3 and the University of Pennsylvania (UPenn)-developed LC-MS/MS method (250 samples); and ADx-EUROIMMUN Beta-Amyloid (1-42) enzyme-linked immunosorbent assay (ELISA) (49 samples). RESULTS High correlation was demonstrated between Elecsys® β-Amyloid (1-42) CSF and comparator assays: INNOTEST® β-AMYLOID(1-42) (Spearman's ρ, 0.954); INNO-BIA AlzBio3 (Spearman's ρ, 0.864); ADx-EUROIMMUN Beta-Amyloid (1-42) ELISA (Pearson's r, 0.925). Elecsys® assay and LC-MS/MS measurements were highly correlated: Pearson's r, 0.949 (Roche Diagnostics-developed method) and 0.943 (UPenn-developed method). CONCLUSION Findings from this multicentre evaluation further support use of the Elecsys® β-Amyloid (1-42) CSF assay to aid AD diagnosis. CSF-based certified reference materials should improve agreement across assays and mass spectrometry-based methods, which is essential to establish a global uniform CSF Aβ42 cut-off to detect amyloid pathology.
Collapse
Affiliation(s)
- Leslie M Shaw
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA.
| | - Oskar Hansson
- Clinical Memory Research Unit, Lund University, VO Minnessjukdomar, Simrisbanv 14/4, 212 24 Malmö, Sweden; Memory Clinic, Skåne University Hospital, Inga Marie Nilssons gata 47, 214 21 Malmö, Sweden.
| | | | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia.
| | - James D Doecke
- The Commonwealth Scientific and Industrial Research Organisation/Australian E-Health Research Centre, Butterfield St & Bowen Bridge Rd, Herston, QLD 4029, Australia.
| | - Qiao-Xin Li
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia.
| | - Sandra Rutz
- Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
| | - Monika Widmann
- Roche Diagnostics GmbH, Sandhofer Str. 116, 68305 Mannheim, Germany.
| | - Andreas Leinenbach
- Roche Diagnostics GmbH, Inselkammerstraße 8, 82008 Unterhaching, Munich, Germany.
| | - Kaj Blennow
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Göteborgsvägen 31, 431 80 Mölndal, Sweden; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Wallinsgatan 6, 431 41 Mölndal, Sweden.
| |
Collapse
|
49
|
Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, von Arnim CAF, Otto M, Christenson RH, Powers JL, Shaw LM, Hansson O, Doecke JD, Li QX, Teunissen C, Tumani H, Blennow K. Elecsys ® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clin Biochem 2019; 72:30-38. [PMID: 31129184 DOI: 10.1016/j.clinbiochem.2019.05.005] [Citation(s) in RCA: 52] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Accepted: 05/19/2019] [Indexed: 01/04/2023]
Abstract
BACKGROUND Total tau (tTau) and phosphorylated 181P tau (pTau) are supportive diagnostic cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease. Manual CSF tau assays are limited by lot-to-lot and between-laboratory variability and long incubation/turnaround times. Elecsys® Total-Tau CSF and Phospho-Tau (181P) CSF immunoassays were developed for fully automated cobas e analyzers, allowing broader access in clinical practice and trials. METHODS Analytical performance, reproducibility, method comparisons with commercially available assays, and lot-to-lot and platform comparability (cobas e 601/411) of the Elecsys® CSF assays were assessed. Tau distributions and concentration ranges were evaluated in CSF samples from two clinical cohorts. RESULTS Both assays showed high sensitivity (limit of quantitation [LoQ]: 63 pg/mL [tTau]; 4 pg/mL [pTau]) and linearity over the measuring range (80-1300 pg/mL; 8-120 pg/mL), which covered the entire concentration range measured in clinical samples. Lot-to-lot and platform comparability demonstrated good consistency (Pearson's r: 0.998; 1.000). Multicenter evaluation coefficients of variation (CVs): repeatability, < 1.8%; intermediate precision, < 2.8%; between-laboratory variability, < 2.7% (both assays); and total reproducibility, < 6.7% (tTau) and < 4.7% (pTau). Elecsys® CSF assays demonstrated good correlation with commercially available tau assays. CONCLUSIONS Elecsys® Total-Tau CSF and Phospho-Tau (181P) CSF assays demonstrate good analytical performance with clinically relevant measuring ranges; data support their use in clinical trials and practice.
Collapse
Affiliation(s)
- Valeria Lifke
- Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany.
| | | | | | | | | | - Monika Widmann
- Amsterdam University Medical Center, Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands.
| | | | - Markus Otto
- Clinic for Neurology, University Clinic Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.
| | - Robert H Christenson
- Department of Pathology, University of Maryland School of Medicine, 655 W Baltimore S, Baltimore, MD 21201, USA.
| | - Jennifer L Powers
- Division of Endocrinology, Metabolism and Lipid Research, School of Medicine, Washington University in St Louis, 660 S Euclid Ave, St. Louis, MO 63110, USA.
| | - Leslie M Shaw
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA.
| | - Oskar Hansson
- Clinical Memory Research Unit, Lund University, VO Minnessjukdomar, Simrisbanv 14/4, 212 24 Malmö, Sweden; Memory Clinic, Skåne University Hospital, Inga Marie Nilssons gata 47, 214 21 Malmö, Sweden.
| | - James D Doecke
- The Commonwealth Scientific and Industrial Research Organisation/Australian E-Health Research Centre, Butterfield St & Bowen Bridge Rd, Herston, QLD 4029, Australia.
| | - Qiao-Xin Li
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia.
| | - Charlotte Teunissen
- Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam University Medical Center, Vrije Universiteit, De Boelelaan 1117, 1081, HV Amsterdam, the Netherlands.
| | - Hayrettin Tumani
- Clinic for Neurology, University Clinic Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.
| | - Kaj Blennow
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Göteborgsvägen 31, 431 80 Mölndal, Sweden; Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Wallinsgatan 6, 431 41 Mölndal, Sweden.
| |
Collapse
|
50
|
Li QX, Varghese S, Sarros S, Stehmann C, Doecke JD, Fowler CJ, Masters CL, Collins SJ. CSF Tau supplements 14-3-3 protein detection for sporadic Creutzfeldt-Jakob disease diagnosis while transitioning to next generation diagnostics. J Clin Neurosci 2018; 50:292-293. [PMID: 29422367 DOI: 10.1016/j.jocn.2018.01.064] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2017] [Revised: 12/05/2017] [Accepted: 01/18/2018] [Indexed: 10/17/2022]
Abstract
The pre-mortem clinical diagnosis of Creutzfeldt-Jakob disease (CJD) is supported by biomarkers, especially cerebrospinal fluid (CSF) 14-3-3 and total tau (Tau) protein levels. These CSF biomarkers have proven the most useful prior to transitioning to powerful next generation diagnostics employing protein amplification techniques such as the real time quaking-induced conversion (RT-QuIC) assay. To enhance national diagnostic capacity while transitioning to RT-QuIC assays an optimized CSF Tau cutoff was determined and shown to usefully supplement 14-3-3 protein detection.
Collapse
Affiliation(s)
- Qiao-Xin Li
- National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia
| | - Shiji Varghese
- National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia
| | - Shannon Sarros
- National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia; ANCJDR, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia
| | - Christiane Stehmann
- National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia; ANCJDR, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia
| | - James D Doecke
- CSIRO Health and Biosecurity, Brisbane, QLD 4029, Australia
| | - Christopher J Fowler
- National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia
| | - Colin L Masters
- National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia; ANCJDR, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia
| | - Steven J Collins
- National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia; ANCJDR, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia; Department of Medicine (RMH), The University of Melbourne, Parkville 3010, Australia.
| |
Collapse
|